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ABSTRACT 
Hepatocellular carcinoma (HCC) presents a global healthcare problem. It is the second most 
lethal cancer worldwide, causing 745,000 deaths annually. HCC accounts for 70% to 90% of 
primary liver cancer cases with rising incidence in developed countries. Newly diagnosed cases 
in the U.S. are expected to increase by 10% in three years. Symptoms of HCC typically do not 
appear until advanced stage, leaving surgical resection the primary therapy. However, HCC 
patients suffer from dire prognosis of less than 5% five-year survival rate and >50% incidence of 
tumor recurrence, due to poor contrast of HCC against surrounding liver tissue limiting resection 
accuracy. Using a molecular imaging system that targets differentially expressed tumor specific 
surface biomarkers may help detect HCC neoplasm missed by surgeons and preserve viable liver 
tissue to reduce recurrence and improve patient recovery. This dissertation presents the HCC 
targeting and imaging methods developed to specifically identify HCC neoplasm with high 
contrast, fast kinetics and deep penetration. 
Two cancer cell surface biomarkers, epidermal growth factor receptor (EGFR) and glypican-3 
(GPC3), are important in the development of HCC. To create a molecular imaging strategy for 
HCC detection, short peptide sequences specifically binding to these biomarkers have been 
selected and validated. They demonstrated high target affinities (kd < 75 nM) and fast cellular 
binding kinetics (<10 min). After conjugating with near-infrared organic dye, these molecular 
targeting probes were able to home to the HCC tumor xenograft in vivo after intravenous 
administration. Ex vivo and in vivo optical imaging was conducted with fluorescent laparoscopy, 
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whole body fluorescent imaging, and hand held dual-axis confocal microscopy. In vivo cell 
surface binding of peptide probe to HCC xenograft in mice was observed at subcellular 
resolution in both horizontal (1000×1000 µm2) and vertical (1000×430 µm2) planes. Tumor 
margins were automatically detected with computerized segmentation algorithm. High target-to-
background ratios (2.99 and 6.2 respectively) were achieved at tumor sites after 6 and 2 hours 
respectively, and targeting probes were cleared from the animal system within 24 hours. In 
addition, targeted in vivo photoacoustic tomography (PAT) imaging visualized probe penetration 
inside the tumor 1.8 cm beneath intact skin.  
Plasmonic nanoparticles absorb light more efficiently than organic dyes. By coating GPC3 
targeting peptide onto gold nanoshell (GNS) surface, in vivo photoacoustic imaging contrast was 
improved from 2.25 to 4.45 and imaging depth reached 2.1 cm. Peak probe uptake in vivo 
occurred at 2 hours and clearance took place within 12 hours, which are desirable 
pharmacokinetics for clinical settings of intraoperative imaging guidance. Specific binding, 
biodistribution and toxicity were investigated in cultured cells, ex vivo tissues (human and mouse) 
as well as in mouse models. The GPC3 targeting probe was able to distinguish HCC from non-
HCC human patient biopsies (n=41) at 93% sensitivity and 88% specificity, with area under the 
receiver operator characteristic curve (AUC) value reaching 0.98. These studies showed that 
affinity peptide based molecular imaging is an enabling technology which will allow clinicians 
to perform functional imaging during surgery to identify resection margin with high contrast, 
sensitivity and speed. 
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Chapter 1 Introduction 
1.1 Hepatocellular carcinoma 
Cancer, and in particular, hepatocellular carcinoma (HCC), presents a global healthcare problem. 
It is found in countries all over the world especially in the Asia-Pacific region [1]. Worldwide, 
HCC is the second most lethal cancer, causing 745,000 deaths annually [2], Figure 1.1. HCC 
has a high incidence rate of 31.4/100K in population [3]. HCC accounts for 70% to 90% of 
primary liver cancer cases [4]. Although it was historically more prevalent in developing 
countries, such as China and India [1], we are now seeing a rising incidence in developed 
countries as well [5]. In the United States, age-adjusted incidence rates of liver cancer more than 
tripled between 1975-2013 [6]. The number of newly diagnosed cases is expected to increase by 
10% in three years [7]. With less than 5% 5-yr survival rate, HCC patients suffer from dismal 
outcome of the disease [8]. 
 
Figure 1.1 Global cancer mortality distribution. Liver cancer is the second most lethal cancer worldwide, following lung cancer, 
and accounted for more than seven million deaths in 2012. Adapted from GLOBOCAN 2012: Estimated Cancer Incidence, 
Mortality and Prevalence Worldwide in 2012, by J. Ferlay, I. Soerjomataram, et al., Retrieved from 
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. 
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1.2 Challenges and motivation  
HCC patients suffer from dire prognosis. Symptoms of HCC typically do not appear until the 
cancer is advanced [7]. Only 10% to 20% of HCC tumors are diagnosed early enough for 
effective treatment [9-11]. Only 10% of patients receive liver transplants due to donor shortage 
[12]. Ablation is another option, usually in combination with other treatment methods [13]. 
Surgical resection remains the primary therapy [14, 15]. Liver resection (LR), also known as 
partial hepatectomy, is a potentially curative surgical treatment option for patients with HCC 
[16]. The goal of LR is to remove the HCC with an adequate margin, while preserving as much 
functional liver parenchyma with minimal blood loss and no complications [17]. Unfortunately, 
the incidence of tumor recurrence is >50% [18]. 
 
Figure 1.2 More than 80% HCC result from HBV related cirrhosis (A) a cirrhotic liver. Adapted from What is a liver transplant, 
2015, retrieved from https://www.ucl.ac.uk/immunity-transplantation/diseases-and-treatments/transplantation/liver (B) multiple 
HCC foci in the background of cirrhotic liver. Adapted from Hepatocellular Carcinoma, by T. Hargrave. 2009, retrieved from 
http://slideplayer.com/slide/7043320. 
The high recurrence rate is largely due to limited resection accuracy because the surgeons often 
cannot discern the exact sites of lesion from the background [19]. Patients with cirrhosis are at 
increased risk for developing HCC [20-22], and represent an important surveillance population 
[23-25]. Since more than 80% HCC cases result from HBV related cirrhosis, Figure 1.2(A), it is 
typical to resect HCC lesion in a background of cirrhotic liver [26]. HCC can have multiple 
small foci and difficult to be distinguished from the surrounding normal liver [27], Figure 1.2(B). 
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The lack of clear tumor margin forces the surgeon to remove more tissue than necessary and 
miss satellite locations [28]. A lack of effective and accurate surgical removal leads to poor 
prognosis resulting from either inadequate liver function or recurrence [29]. Therefore, 
intrasurgical detection with high contrast imaging of tumor biomarkers on transformed cells is 
critical for improving the survival of patients. 
1.3 Molecular targets in cancer 
Differentially expressed and tumor specific molecular targets on cancer cells can be visualized in 
pre-cancerous lesions well before gross architectural changes of cancer become apparent [30], 
and may be useful for early detection [31]. Recently, targeted imaging with peptides has been 
demonstrated as a diagnostic and visualization tool in both preclinical and clinical studies to 
guide surgical margins and enhance therapy in various cancers [32-36]. 
Biomarkers expressed on the plasma membrane are accessible to binding and imaging by 
molecular probes upon systemic delivery through blood and thus adopted as targets for the 
imaging strategy [37-39]. There are intracellular targets and genetic mutations [40-43], or 
proteins expressed on the cell surface, such as epidermal growth factor receptor (EGFR) [44-46], 
Epcam [47], c-MET [48, 49] and cluster of differentiation 24 (CD24), Figure 1.3. Among them, 
cell surface targets, EGFR and GPC3, have been examined in this thesis as molecular targets for 
HCC. Both are known to play important roles in cell proliferation, survival and migration of 
solid tumors including HCC [50-54]. 
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Figure 1.3 Molecular Targets in Cancer. Cancer cell can present a series of surface biomarkers as molecular targets. They are 
accessible for binding and imaging by molecular imaging probes. 
EGFR was targeted first. The first sequencing of the primary liver cancer genome revealed a 
total of 11,731 somatic mutations [55]. Following studies showed that the CTNNB1, TP53, and 
EGFR genes were frequently mutated in liver cancer [56-59]. There is already a known peptide 
targeting it developed for colon cancer [60] and it is known to be exuberantly expressed on the 
membrane of HCC cells [61, 62]. Imaging HCC with EGFR-targeting peptide will provide proof 
of concept evidence for whether the molecular imaging strategy works in liver cancer. 
A second biomarker, Glypican 3, was identified and targeted as well, because biomarkers on 
cancer cells can be heterogeneous [62-64]. Thus, it is important to multiplex different markers in 
order to capture a large percentage of patients [64, 65]. Glypican-3 (GPC3) is a heparan sulfate 
proteoglycan that is not found in normal adult liver, but is anchored to the cell surface of 
neoplastic hepatocytes and thus is accessible for imaging [66, 67]. It regulates the signaling 
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activity of several growth factors including Wnts [68, 69]. GPC3 promotes HCC growth by 
stimulating Wnt signaling, and has expression levels that reflect tumor stage [16]. 
1.4 Peptides as molecular probes 
A variety of molecular probe platforms are available for imaging [70-72]. For instance, 
photoacoustic imaging has used molecular probes for targeted detection [73]. A protease 
sensitive oligomer labeled with Atto-740 was used to detect furin-like activity [74]. However, 
DMSO was needed to improve solubility, and the oligomers were found to aggregate and form 
nanostructures that trapped the reporter molecule inside the cells. For another instance, 
antibodies labeled with gold nanoparticles have been used to image molecular targets, such as 
Her-2, EGFR, CXCR4 and LYVE-1 [75-79]. Antibodies are high in molecular weight (thus 
bigger in size), and have long circulatory half-lives [80]. They also have limited ability to 
extravasate from the vasculature, penetrate into tumor, and clear from interstitial space [80, 81]. 
All of these properties increase imaging background. Antibodies are also prone to 
immunogenicity that limits repetitive use [82]. In contrast, RGD peptides have been used to 
target integrins in tumor-associated blood vessels that arise from angiogenesis and metastasis 
that occur at a late stage of tumor development [83-86]. Compared to antibodies, peptides are 
small in size and molecular weight. Thus, they can extravasate deep into tumor tissue and be 
cleared from the system with fast acting kinetics [87-89]. What takes days for antibody only 
requires hours for peptides [90, 91]. 
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Table 1.1 Molecular probe platforms. A variety of molecular probe platforms (activatable, antibody, aptamer, small molecule, 
lectin and peptide) are available for imaging. They each have different strengths and weaknesses in term of affinity, specificity, 
kinetics, target-to-background (T/B) ratio, cost and immunogenicity. Affinity peptide possesses combination of features that are 
desirable for the clinically relevant molecular imaging strategy for HCC detection. 
Table 1.1 highlights the major strengths and weaknesses of molecular probe platforms. Peptides 
have small size and low molecular weight that result in ideal pharmacokinetic properties for deep 
tissue imaging [91, 92]. Compared with bulky monoclonal antibodies, peptides provide an 
attractive alternative for visualizing tissue targets that would otherwise be difficult to penetrate 
or access [93]. Peptides have high diversity [94, 95], and can achieve high specificity with 
binding affinities on the nanomolar scale [60, 89, 96, 97]. This probe platform has flexibility to 
be labeled with a broad range of fluorophores [60, 89], and is inexpensive to produce in large 
quantities [98, 99]. It is also less immunogenic [100, 101] despite of having lower affinity than 
antibodies [102]. Thus labeled peptides were used in the following studies.  
Peptides can also be used for image-guided surgery. This approach has been demonstrated using 
nonspecific dyes, such as indocyanine green (ICG) [103-105]. By targeting overexpression of 
biomolecules that are specific for HCC, better signal and lower background can be obtained [106, 
107]. Improved visualization of tumor during resection may achieve a better balance between 
complete tumor resection and maintenance of liver function. The remaining volume of “normal” 
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liver parenchyma needed to optimize post-operative function can then be maximized [108, 109]. 
While molecular specificity may also be achieved in theory with frozen sections, at least 30-60 
minutes are required for tissue processing while patients wait under general anesthesia [110]. 
Real time imaging can also be performed intra-operatively with ultrasound [111], but molecular 
specificity is difficult to achieve using this method. 
1.5 Optical imaging as cancer diagnostic method 
Optical imaging combined with molecular targeting is what this study is proposing as imaging 
method for HCC diagnosis. The existing diagnostic methods for HCC include ultrasound, CT, 
MRI and PET/CT scans [107, 112, 113], Table 1.2. These non-optical imaging modalities have 
limited ability to visualize multiple targets concurrently in real time [113]. On the other hand, the 
limitations of optical imaging are lack of penetration depth and use of exogenous contrast agents 
such as fluorescent dyes [114-116]. Combined with molecular targeting, optical imaging 
techniques can provide the speed and resolution needed to observe cellular and molecular events 
in real time [117-119].  
 
Table 1.2 Methods for imaging HCC. Ultrasound is readily available and low in cost, but also has low contrast and resolution. CT 
and MRI are sensitive and high in resolution, but they only provide structural information, with the exception of metabolism 
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information on potential tumors from magnetic resonance spectroscopy (MRS) [120, 121]. PET/CT can offer functional 
information to identify extra hepatic metastasis, but can be costly and slow. Combined with molecular targeting, optical imaging 
techniques can provide the speed and resolution needed to observe cellular and molecular events in real time. 
The NIR window is ideally suited for deep tissue in vivo imaging. The near-infrared (NIR) 
window defines the range of wavelengths from 650 to 950 nm [122], where light has its 
maximum depth of penetration in tissue, Figure 1.4. Minimal light absorption by hemoglobin 
(<650 nm) and water (>950 nm) makes probes absorbing within NIR range particularly useful 
[123]. By tuning the optical absorption of exogenous contrast agents to fall in the “tissue optical 
window” where tissue components have minimal absorption, it is possible to increase the 
imaging depth and contrast [124].  
 
Figure 1.4 Light extinction property of Hb and water. The near-infrared (NIR) window defines the range of wavelengths from 
650 to 950 nm where light has its maximum depth of penetration in tissue. At lower wavelength, hemoglobin (both oxygenated 
and deoxygenated) has higher light extinction and at higher wavelength, fat and water in tissue has increased light extinction. 
These endogenous agents can interfere with the in vivo imaging contrast and depth. 
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With molecular targeting and NIR fluorophore labeling we can improve the contrast and imaging 
depth specifically at tumor site. Antibodies, affibodies, and peptides are being developed for use 
as molecular probes to improve detection specificity with molecular imaging [125-129]. These 
targeting moieties can be labeled with bright fluorescent dyes to achieve high contrast and 
produce near-infrared (NIR) emission for deep tissue imaging [128, 130]. However, clinical 
usefulness of some probes has been limited by slow binding onset, long circulation times, and 
increased background [87, 131]. In contrast, peptides are well-suited for clinical use because of 
rapid binding kinetics, deep tissue penetration, lack of toxicity, and affordable cost [132]. 
Compared with conventional clinical imaging methods, optical imaging of NIR dye labeled 
peptide probes may improve cancer detection in the clinic.  
For deep tissue imaging, probes absorbing in the NIR spectral range are desirable [133]. Two 
NIR contrast agents were attached to targeting probes in this study. One was a NIR fluorescent 
dye, Cy5.5, with peak absorption wavelength at λex = 677 nm [134]. This organic dye label had 
the versatility to be imaged in various fluorescence imaging modalities necessary for ex vivo and 
in vivo validation of probe binding, as well as in photoacoustic tomography imaging to acquire 
depth information [60, 89, 135]. In order to push the contrast of deep tissue imaging further, a 
more optimal photoacoustic contrast agent was employed, namely gold nanoshell with peak light 
extinction wavelength at λex = 770 nm [136, 137]. 
1.6 Summary 
Hepatocellular carcinoma poses a significant medical challenge to global healthcare with limited 
treatment options. Surgical resection is currently the primary potential curative measure for HCC 
patients, but proved ineffective due to difficulty associated with low contrast of tumor margin 
against cirrhotic background during surgery. Therefore, high contrast imaging method that 
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specifically identifies the HCC lesion is critical for patient survival. And molecular targeted 
imaging of HCC with affinity peptide probe operating in the near-infrared spectral range was 
proposed to address the current challenge. Two surface biomarkers on HCC cells, namely EGFR 
and GPC3, were chosen as molecular targets for affinity peptides with deep tissue infiltration and 
fast kinetics. Combined with optical imaging technology, high contrast images in real time can 
be obtained beneath the surface of tissue to provide functional information in detection of cancer 
cells at improved accuracy. 
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Chapter 2 In vivo imaging of EGFR overexpression in cancer 
In this chapter, EGFR targeting peptide previously used to collect fluorescence images 
endoscopically from mouse colonic adenomas with topical administration was labeled with NIR 
dye Cy5.5 and validated in both colorectal dysplasia and HCC cell lines. The use of in vivo 
optical and photoacoustic imaging to visualize HCC xenograft tumors in living mice with a 
peptide specific for EGFR was demonstrate. Peptide probe delivery inside tumor was also 
investigated. This body of work presented here has been published in peer-reviewed literature as 
contribution to the field: [138] for Section 2.2.1, [139] for Section 2.3 and [135] for Section 2.4. 
2.1 Peptide targeting EGFR overexpression  
2.1.1 EGFR as HCC target 
Epidermal growth factor receptor (EGFR) overexpression is important for HCC progression [62]. 
The EGFR pathway plays an essential role in cell proliferation, survival and migration [50-54]. 
EGFR is overexpressed in various cancers including lung [140], breast [141], and esophagus 
[142], pancreas [143], head and neck [144], and was found to promotes solid tumor growth [145]. 
Its altered activity has been implicated in the development and growth of many tumors including 
HCC [146-148]. In previous studies, EGFR has been found to be overexpressed in 40-70% of 
HCC [44, 149-153], most likely contributing to aggressive growth characteristics [154, 155], 
metastasis formation, and resistance to therapy [152, 156-158].  
EGFR has been an attractive target for biologics (e.g. peptide and affibody [127]) or antibodies 
in applications such as tumor-targeted imaging and therapy [159-161]. EGFR has served as 
 12 
 
cancer biomarker and imaging target in previous studies to provide molecular information at 
tumor site after being labeled with different contrast agents including organic dyes [162-164] and 
metallic nanoparticles [77, 79, 165]. The EGFR inhibitor Gefitinib has been found to 
significantly reduce the incidence of HCC in an animal model [150]. Existing evidence led us to 
believe EGFR targeted imaging may improve detection specificity for HCC. 
2.1.2 EGFR targeting peptide 
An ideal platform for cell surface biomarker targeting with clinical translation potential should 
be target specific, fast binding and affordable [166]. A number of targeting platforms have being 
developed for use in precision medicine [167]. They include antibodies [168, 169], antibody 
fragments [170] aptamers [171], small molecules [172], vitamins [173] and lectins [174]. These 
agents were used to provide a biological basis for disease detection, establish patient prognosis, 
guide therapy, and monitor treatment response. Antibodies, such as those against EGFR and 
VEGF, have high specificity and affinity, and have been most commonly used in the clinic [175-
177]. These moieties are large in size, high in molecular weight, and have long plasma half-
lives[178]. High concentrations are needed for therapeutic effect [179, 180], resulting in 
increased costs. The long circulatory time and high cost of antibodies as targeting moiety in 
imaging could potentially inhibit acceptance for clinical translation as a diagnostic tool. This 
motivates our present study to explore feasibility for use of a cost-efficient and fast acting EGFR 
targeting peptide.  
Here, we aim to demonstrate the use of a peptide specific for EGFR to target HCC tumors in a 
pre-clinical xenograft model. In contrast to antibody, peptides have small size and low molecular 
weight that result in ideal pharmacokinetic properties for deep tissue imaging. Peptides clear 
rapidly from non-target tissues, resulting in reduced background [135, 181]. Peptides can be 
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structurally altered to improve stability against proteolytic degradation, increase circulatory half-
life, and enhance capillary permeability [182]. All of these attributes promote deep penetration 
into tissue and more effective targeting [183]. Previously, a peptide specific for domain 2 
(extracellular) of EGFR has been developed [60]. This peptide was used previously to collect 
fluorescence images endoscopically from mouse colonic adenomas with topical administration. 
We now show that specific binding to EGFR can also occur with systemic administration in liver 
cancer mouse model.  
2.1.3 Synthesis of EGFR peptide  
Previously identified EGFR targeting peptide sequence, QRHKPRE (hereafter QRH*), was 
synthesized using standard Fmoc-mediated solid-phase synthesis [184]. We extended the 
monomeric linear peptide with a linker sequence GGGSK (same as the sequence on its 7-mer 
phages display library [185, 186]) to prevent interference of the dye in peptide binding, arriving 
at molecular weight of 1336.48 g/mol. Near-infrared dye Cy5.5 labeled EGFR targeting peptide 
probe, QRH*-Cy5.5, was synthesized by coupling QRH*-GGGSK peptide with water soluble 
sulfo-Cy5.5-N-hydroxysuccinimide ester (Lumiprobe LLC) respectively overnight with N,N-
diisopropylethylamine, followed by HPLC purification. Cy5.5 has a delocalized positive charge 
in its chromophore and possesses high quantum yield (0.22 at 678 nm), good chemical stability, 
easy conjugation, and high sensitivity (mole extinction coefficient ~250,000 mol/cm) [187, 188]. 
The excitation/emission wavelength is 674/692 nm for Cy5.5, where hemoglobin and water have 
their lowest absorption coefficients [189]. 
Cy5.5-labeled peptides using standard Fmoc-mediated solid-phase synthesis was described 
below. We used Fmoc and Boc protected L-amino acids, and synthesis was assembled on rink 
amide MBHA resin. The peptide was synthesized on a PS3 automatic synthesizer (Protein 
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Technologies Inc). The C-terminal lysine was incorporated as Fmoc-Lys (ivDde)-OH, and the N-
terminal amino acid was incorporated with Boc protection to avoid unwanted Fmoc removal 
during deprotection of the ivDde moiety prior to fluorophore labeling. Upon complete assembly 
of the peptide, the resin was transferred to a reaction vessel for manual labeling with the dye. 
The ivDde side chain protecting group was removed with 5% hydrazine in DMF (3x10 min) with 
continuous shaking at room temperature (RT). The resin was washed with dimethylformamide 
(DMF) and dichloromethane (DCM) 3X each for 1 min. The protected resin-bound peptide was 
incubated overnight with Cy5.5-NHS ester (Lumiprobe LLC) with DIEA, and the completion of 
the reaction was monitored by a qualitative Ninhydrin test. Upon completion of labeling, the 
peptide was cleaved from the resin using TFA: TIS: H2O (95:2.5:2.5 v/v/v; Sigma-Aldrich) for 4 
hours with shaking in the dark at RT. After separation of the peptide from the resin, the filtrate 
was evaporated with N2 gas followed by precipitation with chilled diethyl ether and stored 
overnight at -20oC. The precipitate was centrifuged at 3000 rpm for 5 min and washed with 
diethyl ether 3X and centrifuged in between each washing step. The crude peptides were 
dissolved in 1:1 Acetonitrile/H2O (v/v) and purified by prep-HPLC with a C18 column (Waters 
Inc) using a water (0.1% TFA)-acetonitrile (0.1% TFA) gradient. The final purity of the peptides 
was confirmed by analytical C18-column. Further characterization was performed with either 
ESI (Waters Inc) or Q-TOF (Agilent Technologies) mass spectrometry. The scrambled (control) 
peptide PEH*-Cy5.5 was synthesized, labeled, and purified in the same manner, hereafter PEH*-
Cy5.5. After lyophilization, the peptides were stored at -80ºC and dissolved in water at a 
concentration of 300 μM. Molecular graphics and analyses of the peptides were performed with 
the UCSF Chimera package (v. 1.10.2, University of California, San Francisco). 
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Figure 2.1 NIR dye labeled EGFR targeting peptides. (A) Chemical structure of QRHKPRE peptide (black) with GGGSK linker 
(blue) and Cy5.5 fluorophore (red), hereafter QRH*-Cy5.5. (B) Scrambled control peptide PEHKRRQ, hereafter PEH*-Cy5.5. 
As illustrated in the structural schematics, EGFR targeting 7-mer peptide, QRHKPRE (black), 
was labeled on the C-terminus with Cy5.5 (red) via a GGGSK linker (blue), Figure 2.1(A). A 
scrambled control peptide, PEHKPRE, was also synthesized by scrambling the targeting peptide 
sequence without changing the amino acid make up, Figure 2.1(B).  
2.1.4 EGFR targeting probe characterization 
After scrambling the targeting peptide, the 3D structure as well as chemical environment 
changed significantly, Figure 2.2 (A-B), which explains the difference in their target binding 
abilities. The arrows mark the positions of labeled dye, Cy5.5, while the arrow heads indicate the 
starting amino acids in the peptide sequences. This is a computationally modeled structure rather 
than an actual determined structure. Ultimately, X-ray crystallography would determine the most 
accurate structures of purified and crystalized peptides. But such endeavor is beyond the scope of 
this thesis. 
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Figure 2.2 3D space filling structure of EGFR targeting probe and corresponding scrambled control probe. Structural differences 
were observed between (A) targeting and (B) scrambled control peptides. Cy5.5 dye was labeled on C-terminal of each 7-mer 
peptide and the sulfonated benzo-fused indolenine rings are marked with arrows. The N-terminals of peptides where the 7-mer 
sequences begin are denoted with arrow heads. Both the overall shapes and local chemical environments are different in the two 
probes. Color code: grey-C; white-H; red-O; blue-N; yellow-S. 
Using a structural model, a binding energy of Et = -554.81 kcal/mol was found for docking to 
crystal structure of human EGFR complex extracellular domains (Protein Data Bank index: 
1IVO) [60]. By comparison, we found Et = -535.37 kcal/mol for the scrambled (control) peptide, 
PEH*-Cy5.5. In the model, QRH*-Cy5.5 binds to amino acids 230–310 of EGFR (extracellular 
domain 2), Figure 2.3(A). The absorption spectra of QRH*-Cy5.5 and PEH*-Cy5.5 at 100 µM 
concentration in water shows a peak at abs=677 nm, Figure 2.3(B). The fluorescence spectra of 
QRH*-Cy5.5 and PEH*-Cy5.5 at 100 µM concentration in water shows a peak at em=708 nm 
when excited by em=671 nm laser, Figure 2.3(C).  
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Figure 2.3 Modeling of EGFR peptide binding and spectral analysis (A) QRH*-Cy5.5 was found on the structural model (1IVO) 
to bind EGFR extracellular domain 2. (B) Absorbance spectra of Cy5.5-labeled peptides shows peak at λex = 677 nm. (C) 
Maximum fluorescence emission peak occurred at em=708 nm when excited by em=671 nm laser. 
 
Figure 2.4 Purification of EGFR peptide in HPLC. Cy5.5 labeled QRH* peptide is eluded at 27min on HPLC while the unlabeled 
peptide is eluded at 17min. The purity of dye labeled peptide reached 95.34% as quantified by the area under the peaks. 
Cy5.5-labeled peptides were purified to >95% on HPLC, Figure 2.4, detected at 214 nm which is 
absorbed by peptide bonds. This result was confirmed on mass spectrometry. We found a 
molecular weight of 2232.88 g/mol, which agrees with the expected value, Figure 2.5(A-B).  
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Figure 2.5 Mass spectroscopy of Cy5.5 labeled EGFR peptide. Experimental mass-to-charge (m/z) ratios for (A) QRH*-Cy5.5 
and (B) PEH*-Cy5.5 were found to be 2233.89 (with one C-13), and agreed with the expected values. 
2.2 Validation of EGFR targeting peptide 
Unlike in the previous study where the targetability of NIR dye labeled EGFR targeting peptide 
QRH* was validated in colon cancer [60], the Cy5.5 label on QRH* in this study was 
customized and modified with four sulfo-groups to improve its solubility. Therefore, it is critical 
to revalidate its targetability in colon cancer after labeling with the more soluble version of 
Cy5.5 before moving on to its validation and imaging applications in HCC.  
2.2.1 Validation in colonic dysplasia 
We used the same colorectal cancer mouse model for EGFR peptide validation as previously 
described [5]. Transgenic CPC;Apc mouse spontaneously developed pre-malignant (dysplasia) 
lesions in the distal colon where they are accessible by the front-view endomicroscope [190]. 
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These mice are genetically engineered to sporadically delete the APC gene, which is mutated 
in >80 of human colorectal carcinomas [6]. The results presented here were published in peer-
reviewed journal article [138]. 
2.2.1.1 In vivo wide field fluorescent colonoscopy 
Wide field fluorescent colonoscopy helped confirm the peak fluorescence intensity time point 
after EGFR targeting probe injection. Subsequently experiment mice were sacrificed and subject 
to ex vivo binding validations with other imaging methods. During imaging, 12-week-old 
CPC;Apc mice were anesthetized with 2% isoflurane (Fluriso; MWI Veterinary Supply Co.). We 
first used a wide-field small animal endoscope (27030BA, Karl Storz Veterinary Endoscopy) 
with white light illumination to examine the colon for presence of grossly visible adenomas, 
Figure 2.6(A). We waited 90 min after intraperitoneal injection of 300 of QRH*-Cy5.5 
solution in a volume of 600 L to allow the peptide to bind to its target. Increased fluorescence 
signal in colon polyp was observed, Figure 2.6(B) in endoscopic image. Reflectance image had 
even intensity at polyp and surrounding normal tissue,  
Figure 2.6(C), indicating the increased fluorescence signal observed at colon polyp was not due 
to its vicinity to the laser source at the center. No auto-fluorescence was detected in mouse colon 
prior to peptide injection. 
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Figure 2.6 In vivo small animal endoscopy of colonic adenoma in mouse. (A) White light image of CPC;Apc mouse colon 
collected in vivo with wide-field endoscope shows location of spontaneous adenoma (arrow). (B) Maximum uptake of the NIR-
labeled EGFR peptide QRH*-Cy5.5 is seen from the adenoma ~90 minutes after systemic administration. (C) Reflectance image 
at the same field of view. 
2.2.1.2 Macroscopic fluorescent imaging 
After completion of In vivo wide field fluorescent colonoscopy imaging, the animals were 
euthanized, and the colon was excised, flushed with PBS, and divided longitudinally for 
macroscopic imaging (IVIS 200, Caliper Life Sciences), to validate specific uptake of QRH*-
Cy5.5 by adenomas. NIR fluorescence images were collected using a Cy5.5 filter with λex = 675 
nm excitation and 720 nm emission with 0.05 sec exposure. A ruler was placed next to the 
specimen to determine the distance from the anus for registration with the endoscopy and 
histology images.  
Representative NIR fluorescence image showed increased fluorescence intensity from adenomas 
(lower dotted rectangle) compared with adjacent normal colonic mucosa (upper dotted rectangle), 
Figure 2.7(A). Fluorescence intensities were measured from rectangular regions of interest (ROI) 
around the dysplasia and a rectangle of equal area over adjacent normal (Living Image 4.0 
software PerkinElmer). The intensity was defined by the sum of the radiance from each pixel 
inside the ROI/number of pixels (photons/s/cm2/sr). The target-to-background ratio for each 
adenoma was calculated by dividing average radiance in ROI of dysplasia with that of normal 
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colon. We measured a T/B ratio of 3.47±1.87 from n = 6 mice. The co-registered white light 
image confirms the locations of adenomas, Figure 2.7(B). 
 
Figure 2.7 Macroscopic fluorescent imaging of peptide binding to colonic adenoma. (A) Representative NIR fluorescence image 
collected ex vivo showed selective uptake of QRH*-Cy5.5 in adenomas compared with adjacent normal colonic mucosa. 
Intensities were measured from the ROIs defined by the dotted rectangles. We calculated a mean T/B ratio of 3.47±1.87 from the 
group of n = 6 mice. (B) Co-registered white light image of exposed mucosal surface confirms locations of adenomas. 
2.2.1.3 Microscopic immunofluorescent staining 
Resected adenomas and normal colonic mucosa from n = 6 mice were cut in 5 μm thick sections, 
and mounted onto glass slides (Superfrost Plus, Fischer Scientific). The tissues were 
deparaffinized, and antigen retrieval was performed using standard methods. Briefly, the sections 
were incubated in xylene for 3 min three times, washed with 100% ethanol for 2 min two times, 
and washed with 95% ethanol for 2 min two times. Rehydration was performed by washing the 
sections twice in dH2O for 5 min. Antigen unmasking was performed by heating the slides in 
10mM sodium citrate buffer with 0.05% Tween at pH 6.0, and then maintaining at a sub-boiling 
temperature for 15 min. The slides were cooled for 30 min. The sections were washed three 
times in dH2O for 3 min, Blocking was performed with DAKO protein blocking agent (X0909, 
DAKO) for 1 hour at RT, followed by rinsing with PBS. The sections were then incubated with 
1:1000 dilution of primary monoclonal mouse anti-EGFR antibody (Thermo Scientific, #MS-396, 
clone 199.12, IgG2a isotype) overnight at 4 °C. Afterwards, the sections were washed 3X with 
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PBS, and further incubated with 1:500 dilution of AF488-labeled secondary goat anti-mouse IgG 
antibody (Life Technologies, #A-11029) for 1 hour at RT, washed 3X, and then mounted on 
glass slides with ProLong Gold reagent containing DAPI (Invitrogen) ) using #1 cover glass (1.5 
μm thickness). Confocal fluorescence images were collected with AF488 and DAPI filters using 
a confocal microscope (Leica TCS SP5 Microsystems). The mean fluorescence intensities from 3 
boxes with dimensions of 30×30 μm2 located completely within the surface epithelium of each 
specimen were measured. Regions that showed saturated intensities were avoided. 
In parallel, we validated specific binding of the EGFR peptide to pre-cancerous crypts with 
immunofluorescence. Fresh whole mount tissues from sacrifice mice at 90 min post i.p. injection 
of EGFR targeting probe was imaged with confocal microscope (Leica SP5 Upright, Germany) 
with Cy5.5 and DAPI filters. The colon was then fixed in 10% buffered formalin and paraffin 
embedded for routine histology (H&E). Sections were cut in the plane parallel to the mucosal 
surface. A low magnification view shows specific staining of the EGFR peptide to dysplastic 
crypts, Figure 2.8(A) and Video 2.1. On the magnified view of dashed red box in Figure 2.8(A), 
increased intensity (arrow) is seen at the cell surface of dysplastic colonocytes, Figure 2.8(B). A 
similar result is found for AF488-labeled anti-EGFR antibody to an adjacent section, Figure 
2.8(C). We observed greatly reduced staining of both the EGFR peptide and antibody to sections 
of normal colon, Figure 2.8(D-F). Representative histology (H&E) is shown for dysplasia and 
normal, Figure 2.8(G-H). The mean fluorescence intensities from 3 boxes with dimensions of 
30×30 μm2 located completely within the surface epithelium of each specimen were measured. 
Regions that showed saturated intensities were avoided. We found significantly greater mean 
fluorescence intensities for dysplasia compared with that of normal in n = 6 mice, Figure 2.8(I). 
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Figure 2.8 Immunofluorescence staining of EGFR targeting peptide to mouse colonic adenoma. (A) Strong fluorescence intensity 
is seen from staining of the EGFR peptide QRH*-Cy5.5 to dysplasia. Magnified view of dashed red box in (A) show specific 
binding of (B) the peptide (arrow) and (C) known AF488-labeled anti-EGFR antibody (arrow) to the surface of dysplastic 
colonocytes. (D) Minimal uptake of QRH*-Cy5.5 is seen in normal colonic mucosa. Magnified views of dashed red box in (D) 
show faint binding of (E) the peptide (arrow) and (F) AF488-labeled anti-EGFR antibody (arrow) to surface of normal 
colonocytes. Representative histology (H&E) of (G) dysplasia and (H) normal colonic mucosa. (I) Confocal microscopy images 
from n = 6 mice showed a mean±SD fluorescence intensity for dysplasia that was significantly greater than that for normal with 
QRH*-Cy5.5, 114.3±21.8 versus 36.8±14.9, *P = 3.0×10-5, and AF488 anti-EGFR antibody, 99.1±16.1 versus 28.4±10.7, *P = 
3.5×10-4, respectively, by paired two-way t-test. 
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Video 2.1 Peptide (red) binding to whole mount mouse colon polyp 2D flythrough 
2.2.1.4 Microscopic immunohistochemical staining 
We then performed immunohistochemistry on sections of mouse colon with EGFR antibody. 
Formalin-fixed sections of human HCC and normal liver were deparaffinized, and antigen 
retrieval was performed using standard methods. Briefly, the sections were incubated in xylene 
for 3 min 3X, washed with 100% ethanol for 2 min 2X, and washed with 95% ethanol for 2 min 
2X. Rehydration was performed by washing 2X in dH2O for 5 min. Antigen unmasking was 
performed by heating the slides in 10 mM sodium citrate buffer with 0.05% Tween at pH 6.0, 
and then maintaining at a sub-boiling temperature for 15 min. The slides were cooled for 30 min. 
The sections were washed 3X in dH2O for 3 min, and then incubated in 3% H2O2 in H2O for 10 
min. The sections were washed 3X in dH2O for 2 min and in PBST for 5 min. We used 1:500 
dilution of polyclonal goat anti-rabbit antibody (GαR; Cell Signaling Technology, #2232). 
Blocking was performed with DAKO protein blocking agent (X0909, DAKO) for 45 min at RT. 
The sections were incubated overnight at 4ºC and then washed in PBS for 5 min 3X. A 1:200 
dilution of secondary antibody (goat anti-rabbit IgG) was added to each section and incubated for 
30 min at RT. The secondary antibody solution was removed by washing 3X with PBS for 5 min. 
Pre-mixed Elite Vectastain ABC reagent (Vector Labs) was added to each section and incubated 
for 30 min at RT. The sections were washed 3X in PBST for 5 min, and developed with DAB 
substrate. The reaction was monitored for 3 min, and then quenched by immersing the slides in 
dH2O. Hematoxylin was added as a counterstain for ~20 sec, and the sections were dehydrated in 
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increasing concentrations of ethyl alcohol (70%, 80%, 95% 2X, 100% 2X). Coverslips were 
attached using permount mounting medium (Fisher, #SP15-100) in xylene. Much higher 
expression in dysplasia, Figure 2.9(A) than normal colon tissue of the mouse was observed on 
immunohistochemistry, Figure 2.9(B). 
 
Figure 2.9 IHC of EGFR expression in colon dysplasia. Representative immunohistochemistry images of (A) dysplasia and (B) 
normal colonic mucosa. 
2.2.2 Validation in HCC 
As Section 2.2.1 demonstrated, EGFR peptide probe with highly soluble Cy5.5 label, QRH*-
Cy5.5, proved to bind specifically to EGFR overexpression in colorectal dysplasia. This 
prompted us to examine its performance in a different cancer, HCC. Some quick and simple 
experiments to see if QRH*-Cy5.5 probe actually binds to EGFR on surface of human HCC cell 
lines were first conducted in vitro before in vivo delivery and imaging in HCC mouse model was 
undertaken.  
2.2.2.1 EGFR expression in HCC cell lines 
Rather than mouse tissue, three human HCC cell lines with high, low and negative EGFR 
expression levels were used to validate specific peptide probe binding to EGFR. Human HCC 
cells, SK-Hep1, Hep3B and HepG2, were purchased from the ATCC (Manassas, VA) and 
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cultured in Eagle's Minimum Essential Medium (EMEM). All cells were cultured at 37ºC in 5% 
CO2, and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. 
Western blot was performed using a 1:1000 dilution of primary polyclonal rabbit anti-EGFR 
antibody (#2232S, Cell Signaling Technology) per manufacturer instructions. Loading was 
controlled with a 1:500 dilution of monoclonal mouse anti--tubulin (#32-2600, Invitrogen). 
Western blot of cells was shown in Figure 2.10. The differential EGFR expression levels in these 
three HCC cell lines served as the testing field for the specificity of EGFR binding by peptide 
probe. Binding intensity in each cell line was expected to correlate with EGFR abundance and 
was measured through the fluorescence signal on immunofluorescent imaging. 
 
Figure 2.10 Western blot shows EGFR expression levels for HCC cells. EGFR has a molecular weight of 170 kDa and is 
overexpressed in SK-Hep1 cells, moderately expressed in Hep3B cells and didn’t express in HepG2 cells. Loading control was 
performed with tubulin (molecular weight = 50 kDa). 
2.2.2.2 In vitro immunofluorescent imaging 
~103 cells (SK-Hep1 Hep3B and HepG2) were grown on coverslips to ~80% confluence, washed 
with PBS and incubated with 5 µM of QRH*-Cy5.5 and PEH*-Cy5.5 for 10 min at RT 
respectively. The cells were then washed 3X in PBS, fixed with ice cold 4% paraformaldehyde 
(PFA) for 10 min, washed 1X with PBS, and then mounted on glass slides with ProLong Gold 
reagent containing DAPI (Invitrogen). Confocal fluorescence images were collected with Cy5.5, 
and DAPI filters. Confocal microscopy (Leica Inverted SP5X) was performed using a 63X oil-
 27 
 
immersion objective. Fluorescence intensities from 5 cells in 2 independent images were 
quantified using custom Matlab (Mathworks) software. For antibody staining, the cells were pre-
fixed with cold methanol for 10 min at -20ºC and blocked with 2% BSA for 30 min at RT. Cells 
were incubated with 1:1000 dilution of anti-EGFR antibody overnight at 4ºC. The cells were 
washed 3X with PBS and processed for secondary staining. Goat-anti rabbit Alexa-Fluor 488 
(AF488) was added to the cells and incubated for 1 hour at RT. Cells were further washed 3X 
with PBS and mounted onto glass cover slips.  
 
Figure 2.11 Immunofluorescent staining of EGFR peptide on HCC cell lines. On confocal microscopy, we observed fluorescence 
at the surface (arrow) of (A) SK-Hep1, (B) Hep3B, and (C) HepG2 cells that have different levels of EGFR expression after 
incubation with QRH*-Cy5.5. D-F) Minimal signal is observed with PEH*-Cy5.5 for all cells. 
On confocal microscopy, we assessed binding of QRH*-Cy5.5 and PEH*- Cy5.5 to human HCC 
cells SK-Hep1, Hep3B, and HepG2 cells that expressed different levels of EGFR, respectively. 
For QRH*-Cy5.5, we observed different strengths of binding to the cells, Figure 2.11(A–C). 
High resolution confocal imaging allowed for clear visualization a thin ring of staining from cell 
surface binding (arrows). Minimal binding was observed for PEH*-Cy5.5 (control) to all cells, 
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Figure 2.11(D–F). Additional validation with siEGFR knockdown experiment was performed 
previously on EGFR overexpressing cell line, HT29, with both peptide and EGFR antibody [60]. 
We measured significantly greater fluorescence intensity from QRH*-Cy5.5 compared to PEH*-
Cy5.5 for SK-Hep1 and Hep3B cells but not for HepG2, Figure 2.12. Quantified measurements 
showed that QRH*-Cy5.5 has significantly greater intensities than PEH*-Cy5.5 on binding to 
SK-Hep1 and Hep3B cells (5.72 and 6.57 fold-change, P=1.63×10-5 and 1.05×10-5, respectively). 
A non-significant difference was found for HepG2 cells (1.02 fold-change, P=0.91). Differences 
between QRH*-Cy5.5 and PEH*-Cy5.5 for SK-Hep1 and Hep3B were significantly greater than 
that for HepG2 (5.63 and 6.46 fold-change, P=1.25×10-4 and 8.12×10-5, respectively). We fitted 
two-way ANOVA models with terms for 3 cell lines, 2 peptides, and their interactions to log-
transformed data. Measurements are an average of 5 randomly chosen cells on 2 slides for each 
condition.  
 
Figure 2.12 Quantification of peptide staining on HCC cell lines. Quantified measurements showed that QRH*-Cy5.5 has 
significantly greater intensities than PEH*-Cy5.5 on binding to SK-Hep1 and Hep3B cells (5.72 and 6.57 fold-change, 
P=1.63×10-5 and 1.05×10-5, respectively). A non-significant difference was found for HepG2 cells (1.02 fold-change, P=0.91). 
Differences between QRH*-Cy5.5 and PEH*-Cy5.5 for SK-Hep1 and Hep3B were significantly greater than that for HepG2 
(5.63 and 6.46 fold-change, P=1.25×10-4 and 8.12×10-5, respectively). 
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2.3 In vivo optical imaging of EGFR in HCC 
The ex vivo and in vitro validations in Section 2.2 of QRH*-Cy5.5 probe binding to EGFR in 
both colorectal dysplasia tissue and HCC cell lines respectively have provided valuable evidence 
of QRH*-Cy5.5 probe’s ability to detect cell surface EGFR overexpression in multiple cancer 
types. Rather than being applied directly onto tumor cells as in the in vitro experiment before, 
animal tumor model challenges the delivery of peptide to tumor site after injecting it into the 
blood stream of the mouse. Therefore, the probe’s performance in in vivo imaging of HCC 
mouse model would inform the potential of clinical translation value of the probe in HCC 
patients. The results presented here were published in peer-reviewed journal article [139]. 
2.3.1 Customized laparoscopic fluorescence imaging system 
To investigate the feasibility of using peptide probe for intraoperative surgical guidance, a 
standard laparoscope used during hepatobiliary surgery on human patients was customized to 
detect fluorescent signal. NIR laser was delivered through the light guide, while both reflectance 
and fluorescence signals from the tumor were collected to detect the location of tumor during 
surgery.  
 
Figure 2.13 NIR fluorescence laparoscope. An imaging module that contains the optics, filters, and cameras was attached to the 
the proximal end of a standard laparoscope used for surgical resection of HCC. Fluorescence excitation at λex = 671 nm was 
delivered through a fiber optic light guide attached on the side. 
We used a standard surgical laparoscope (#49003 AA, HOPKINS® II Straight Forward 
Telescope 0°, Karl Storz) that is commonly used by surgeons to perform radical resection of 
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HCC. The laparoscope was ~10 mm in diameter and had a 31 cm length rigid sheath to collect 
reflectance and fluorescence concurrently. On the proximal end, we attached either a color 
camera to collect conventional white light images or an imaging module to collect co-registered 
reflectance and fluorescence images, Figure 2.13. Reflectance was used to help identify the 
location of the tumor when the color camera is not attached. Excitation at ex = 660 nm was 
delivered into the fiber optic light guide. The imaging module contained the optics, filters, and 
cameras. This instrument was handled easily by a hepatobiliary surgeon (Dr. Zhao Li) who is 
experienced with laparoscopic procedures. 
 
 
Figure 2.14 Customized laparoscope system schematic. Light exiting laparoscope is split by dichroic filter (DF). Reflectance at 
λex = 660 nm is attenuated by neutral density filter (ND) and focused by objective (O1) onto CCD1. NIR fluorescence is bandpass 
filtered (BPF) at center wavelength λ = 716 nm over a 40 nm band and is focused by objective (O2) onto CCD2. 
 
The above schematic explains the optical design of light collection in reflectance and 
fluorescence arms, Figure 2.14. A solid state diode laser (660-S, Toptica Photonics) delivered 
excitation at ex = 660 nm into the fiber optic light guide of the laparoscope. Reflectance light 
entering the laparoscope was reflected by a dichroic mirror DM (FF685-Di02-25x36, Semrock) 
through a neutral density filter ND (Thorlabs, #ND10B), and was focused by an achromatic 
doublet O1 (49-766, Edmund Optics) onto a color CCD camera CCD1 (#GX-FW-28S5C-C, 
Point Grey Research).  
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On the other optical arm, fluorescent light entering the laparoscope passed through a bandpass 
filter BPF (67-039, Edmund Optics) with 40 nm bandwidth centered at 716 nm, optical density 
OD ≥6.0, and 93% transmission efficiency and was focused by an achromatic doublet O2 (49-
766, Edmund Optics) onto a monochromic CCD camera CCD2 (Point Grey Research, #GX-FW-
28S5M-C). Both cameras weighed 86 grams, and collected images with a maximum of 2.8 
megapixels, 1932×1452 resolution, and 26 frames per second. The imaging module weighed 977 
grams (2.15 lbs), and did not interfere with handling of the laparoscope during the imaging 
procedure. 
2.3.2 Mouse model of HCC overexpressing EGFR  
In order to simulate the EGFR overexpressing HCC tumor and test the delivery of QRH*-Cy5.5 
probe to tumor site in a surgical resection setting, a mouse xenograft model with implanted 
human HCC cell line overexpressing EGFR (confirmed by Western Blot, Figure 2.10), SK-Hep1, 
was adopted. SK-Hep1 cells were diluted in growth factor reduced (GFR) Matrigel Matrix 
(Corning), and subcutaneously injected into one flank of female (to avoid male dominance 
within a cage) nude athymic mice (nu/nu, Jackson Laboratory) at 4 to 6 weeks of age with 
weight between 20 to 25 grams. 5×106 cells were implanted per mouse. Anesthesia was induced 
and maintained via a nose cone with inhaled isoflurane mixed with oxygen at a concentration of 
2 to 4% at a flow rate of ∼0.5 L/min for all in vivo animal experiments. Tumor growth and 
volumes were monitored weekly with both ultrasound (US) and magnetic resonant imaging 
(MRI) for 12 weeks (experiment end point) post implantation as described below. 
2D ultrasound (US) images were collected from each xenograft tumor using a portable 
ultrasound scanner (SonixTablet, Ultrasonix, Analogic Corp) designed for small animal imaging. 
During image acquisition, the mice were placed on a heated stage. Anesthesia was induced and 
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maintained with 2% isofluorane (Fluriso; MWI Veterinary Supply Co.). Warm (37°C) ultrasound 
gel (Aquasonic 100, Parker Laboratories) was applied to the tumors. The ultrasound transducer 
(40 MHz) was used in B-mode, and translated along the length and width of the tumor. 3 images 
were taken in each direction to calculate tumor volume. Each image had a 12×12 mm2 field of 
view with an in-plane pixel resolution of 50×50 µm2 [191]. 
Volumes of tumors were estimated as ellipsoid using abc/6, where a, b, and c are dimensions 
measured from the US images [192]. a is defined by the largest dimension in the sagittal plane, 
while b is the value perpendicular to a. c is the parameter orthogonal to both a and b in the 
transverse plane. Each measurement was performed 3 times [193]. SK-Hep1 cells were 
inoculated subcutaneously in n = 8 nude mice at 4 to 6 weeks of age. 
Tumor size was confirmed with MRI images collected with a 7T horizontal bore small animal 
MRI system (SGRAD 205/120/HD/S, Agilent Technologies) using a volume-based 
transmit/receive quadrature radio frequency coil with an inner diameter of 3.5 cm. The animals 
were given an intra-peritoneal (i.p.) injection of macrocyclic gadolinium chelate (Gadoteridol, 
ProHance) at a dose of 2.5 mmol Gd/kg body weight. Body temperature was maintained at 37°C 
by blowing hot air into the magnet through a feedback control system. 12 to 15 min after 
injection of gadolinium, transverse T1-weighted sections were acquired with a scout sequence in 
3 orthogonal axes to identify tumor location. A 256×128 matrix was obtained in 5 min by 
conventional spin-echo multi-slice pulse sequence using repetition time (TR) = 8.5 ms, echo time 
(TE) = 2.6 ms, average = 2, in-plane field of view (FOV) = 35×35 mm2, 25-mm slab thickness of 
1 mm thick interleaved slices with no gap in between. Tumor volume was assessed with the 
freehand region of interest (ROI) function of NIH Image J software. Areas were measured on 
each MRI slice (1 mm thickness) and added together to reconstruct the 3D tumor volume.  
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Representative images of subcutaneous HCC tumor (arrow) at 6 weeks post-inoculation are 
shown with ultrasound (US), Figure 2.15(A), and MRI (T1 weighted contrast-enhanced), Figure 
2.15(B). A peak tumor volume (±SD) of 761±160 and 936±148 mm3 was found on US and MRI, 
respectively, Figure 2.16(A). A correlation of r = 0.98 was found between tumor size on US and 
MRI, Figure 2.16(B). Log-log plot was suggested by biostatistician to reduce overlap and better 
visualize data points smaller in value given the large range in volumes. The transformation did 
not contribute to the goodness of fit (for comparison, r = 0.995 by linear regression without log 
transformation).  
 
Figure 2.15 Mouse xenograft monitoring with ultrasound and MR imaging. Representative images of subcutaneous HCC tumor 
(arrow) at 6 weeks post-inoculation are shown with (A) ultrasound (US) and (B) MRI (T1 weighted contrast-enhanced). 
Since small HCC lesions are easily missed during surgery, it is desirable to have smaller tumor 
size in order to test the sensitivity of peptide probe to detect tumor. Therefore, imaging was 
performed at 6 weeks post implantation before exponential growth would take place. 
 34 
 
 
Figure 2.16 Tumor growth curve and correlation of two imaging methods. (A) Mean (±SD) dimensions for n=8 tumors from US 
and MRI images from post inoculation weeks 1-12 are shown. (B) Positive correlation of r=0.98 was found for tumor size 
measured with US and MRI. 
2.3.3 Pharmacokinetics of EGFR peptide in HCC 
The peak and clearance time points following systemic delivery of peptide probe are important 
metrics for its clinical application during guided surgery. These pharmacokinetics parameters 
were assessed with a time course imaging study in HCC xenograft bearing mice. The mice were 
first anesthetized via a nose cone with inhaled isoflurane mixed with oxygen at a concentration 
of 2 to 4% and flow rate of ∼0.5 L/min. The peptides were injected via tail vein at a 
concentration of 150 mΜ (i.e. 2.7mg/kg) in a volume of 200 μL 6 weeks after inoculation when 
the tumors reached 1-2 cm in size. Imaging was performed first using a standard color camera 
(S3 3-chip camera head, Storz) with white light illumination, Figure 2.17(A, H). Then, the laser 
was directed into the light guide of the laparoscope, and the imaging module was attached to 
collect reflectance/fluorescence concurrently. Fluorescence images from the HCC xenograft 
tumors in intact mice were collected over time (0-24 hrs). Representative fluorescence images 
were shown in Figure 2.17(B-G). The same experiment was repeated with scrambled control 
peptide over the same period of time on different group of mice, Figure 2.17(I-N). Images were 
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collected at 5 frames/sec with a laser power of 1.2 mW. Mice were fed alfalfa-free diet 
(TD.97184, Harlan Teklad, WI) to prevent auto fluorescence from chlorophyll in food. 
 
Figure 2.17 Pharmacokinetics of EGFR peptide in HCC xenograft. (A, H) White light images of HCC subcutaneous xenograft 
tumors in live mice. (B-G) Representative fluorescence images from the HCC xenograft tumors in intact mice were collected 
over time (0-24 hrs) to evaluate the pharmacokinetics for tumor uptake of QRH*-Cy5.5 peptide. (I-N) Representative 
fluorescence images for scrambled control peptide PEH*-Cy5.5. (O)T/B was measured from HCC xenograft tumors (n = 13 
tumors , n = 5 mice) over time following injection of either QRH*-Cy5.5 or PEH*-Cy5.5. For QRH*-Cy5.5, the TBR achieved a 
maximum value of 2.53 ± 0.20 at 6 hours. For PEH*-Cy5.5, the T/B was significantly less at each time point, *P < 0. 01 by 
unpaired t-test. 
Fluorescence intensities from n = 13 HCC xenograft tumors (from n = 5 mice) for both QRH*-
Cy5.5 and PEH*-Cy5.5 were quantified to evaluate the time course for maximum uptake and 
clearance, Figure 2.17(O). After the peptide injection, the target-to-background ratio was 
measured every hour until the maximum value was observed. For QRH*-Cy5.5, the T/B 
exceeded 2.0 after the first hour, and reached a peak value of 2.53 ± 0.20 at 6 hours. After 24 
hours, the peptide appeared to clear from the circulation, and the T/B ratio dropped back to 1. 
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The T/B ratio for PEH*-Cy5.5 was significantly less than that for QRH*-Cy5.5 at each time 
point. 
2.3.4 In vivo laparoscopic images of HCC xenograft 
To assess the feasibility of image guided resection with peptide probe, the xenograft tumors were 
exposed to examine the tumor margins at the peak uptake time 6 hours post probe injection. 6 
hours after injection of QRH*-Cy5.5, a wide excision was performed in the skin overlying the 
xenograft tumors for direct laparoscopic visualization. Representative white light (Video 2.2, 
reflectance (Video 2.3), and fluorescence (Video 2.4) videos are shown, along with 
representative images collected with QRH*-Cy5.5, Figure 2.18(A-C), and PEH*-Cy5.5, Figure 
2.18(D-F). For QRH*-Cy5.5, we observed strong fluorescence signal from the HCC xenograft 
tumors with high contrast and clear tumor margins. For PEH*-Cy5.5, we found only minimal 
fluorescence intensity. We measured the T/B ratio from HCC xenograft tumors (n = 13 tumors 
from n = 5 mice), and found a significantly greater contrast for QRH*-Cy5.5 than for PEH*-
Cy5.5 of 2.99 ± 0.22 versus 1.81 ± 0.16, P<0.0001 by unpaired t-test, Figure 2.18(G). Despite of 
our effort to implant HepG2 xenografts to serve as negative control and benchmark the EPR 
effect, it was not achievable for this cell line is non-tumorigenic [194].  
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Video 2.2 Laparoscopic white light HCC image 
 
Video 2.3 Laparoscopic reflectance HCC image 
 
Video 2.4 Laparoscopic fluorescence HCC image 
 
Figure 2.18 In vivo laparoscopic images of HCC xenograft. (A) White light, (B) reflectance, and (C) fluorescence images 
collected with EGFR peptide QRH*-Cy5.5. (D) White light, (E) reflectance, and (F) fluorescence images collected with 
scrambled (control) peptide PEH*-Cy5.5. (G) A significantly greater target-to-background ratio from HCC xenograft tumors for 
QRH*-Cy5.5 (n = 13 tumors from n = 5 xenograft mice) than for PEH*-Cy5.5 (n = 13 tumors from n = 5 xenograft mice) of 2.99 
± 0.22 versus 1.81 ± 0.16 from the in vivo images, P < 0.0001 by unpaired t-test. 
2.3.5 Automatic ROI recognition 
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Fluorescence, reflectance, and white light images were collected with the NIR laparoscope after 
intravenous injection of the EGFR peptide. A heat map of fluorescent signal was used to 
automatically identify regions of interest (ROIs) with an edge-detecting segmentation algorithm. 
This takes the guesswork out of the equation for surgeons and adds confidence to the clinical 
application of the peptide probe. 
Fluorescence and reflectance images, Figure 2.19(A-B), were collected with the NIR laparoscope 
6 hours after intravenous injection of the EGFR-targeting peptide, QRH*-Cy5.5, in SK-Hep1 
xenograft bearing mice. The same set of images were collected with scrambled peptide PEH*-
Cy5.5 in different group of tumor bearing mice, Figure 2.19(E-F), but no tumors were detected. 
White light images were collected for mice injected with targeting peptide QRH*-Cy5.5, Figure 
2.19(I), and scrambled peptide PEH*-Cy5.5, Figure 2.19(J). 
Fluorescence images of mouse HCC xenograft taken at 6 hrs post peptide injection were 
registered with corresponding reflectance images taken simultaneously. The fluorescence 
intensity of each pixel in the image was divided by intensity of corresponding pixel in the 
reflectance image in order to account for the difference in distance between each pixel and the 
laser source. A heat map image was generated from the resulting ratios at each pixel. Image 
segmentation was performed automatically by custom Matlab (Mathworks) software program 
using Ostu’s Method [62]. Target-to-background ratio of each processed image was calculated 
by dividing the average intensity of pixels inside the segmented tumor and that of those within 
30 pixels outside of segmentation outline. 
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Figure 2.19 Automatic ROI recognition. (A) Fluorescence and (B) reflectance images of exposed xenograft tumor in live mice 
were collected with the NIR laparoscope 6 hours after intravenous injection of QRH *-Cy5.5. (C) Heat map corrects for imaging 
distance by taking the ratio between co-registered fluorescence and reflectance images. (D) Region of interest was segmented by 
imaging processing algorithm using ratio image. (I) Representative white light images of mouse injected with QRH*-Cy5.5 and 
(J) PEH*-Cy5.5. (K) Immunofluorescence image of fresh resected HCC tumor xenograft in whole mount 6 hours after QRH*-
Cy5.5 injection showed surface staining (arrowheads) of peptide probe on individual HCC cells of the tumor. (L) 
Immunohistochemical image of EGFR antibody staining (arrowheads) on fresh resected HCC tumor xenograft. (E-H) The same 
set of images were collected with scrambled peptide PEH*-Cy5.5 in a different tumor. 
Heat map digital image that rectifies imaging distance was generated by taking the ratio between 
corresponding fluorescence and reflectance images pixel by pixel, Figure 2.19(C). Region of 
interest (ROI) was segmented by automatic imaging processing from ratio image following 
Otsu’s method, Figure 2.19(D). The same set of images were analyzed for scrambled peptide 
PEH*-Cy5.5 in a different group of tumor bearing mice, Figure 2.19(G-H).  
Hoechst 33342 (H1399, Life Technologies) at a dose of 10 mg/kg diluted in 200 μL of PBS was 
delivered intravenously via a tail vein injection to stain the cell nuclei 30 minutes before 
sacrificing the mouse. Xenograft tumors were resected and confocal fluorescence images were 
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collected with Cy5.5 and DAPI filters 50μm beneath the surface using a confocal microscope 
(Leica SP5X Upright 2-Photon Confocal Microscope). Immunofluorescence image of fresh 
resected HCC tumor xenograft in whole mount 6 hours after QRH*-Cy5.5 injection showed 
intense cell surface staining (arrowheads) of peptide on human HCC cells under confocal 
microscopy to confirm the specific cell binding, Figure 2.19(K). Immunohistochemical image of 
EGFR antibody staining (arrowheads) on fresh resected HCC tumor xenograft, Figure 2.19 (L), 
confirmed EGFR expression in tumor as would have been done in a clinical setting. 
To quantify the accuracy of the computerized ROI algorithm, an independent observer was asked 
to view white light images of tumor and mark the positions of the center of tumors without any 
prior information on the purpose of the experiment or exposure to the computerized ROI graphs. 
Afterwards, the human-identified tumor centers were overlaid on the computerized ROI. If the 
human-identified tumor center fell inside the computer generated ROI, then it was considered a 
successful identification. All 13 tumors from 5 mice injected with QRH*-Cy5.5 peptide were 
identified with computerized ROI while the PEH-Cy5.5 injected tumors had centers positioned 
outside of the ROIs. 
2.3.6 Post imaging validation of EGFR expression ex vivo 
In addition to fluorescent in vivo imaging at the surface of xenograft tumor, harvested tumor post 
laparoscopic imaging was sectioned and microscopically imaged to confirm the delivery of 
peptide probe to the interior of tumor by i.v. injection. After in vivo imaging was completed, 
mice were euthanized, and their tumors were excised and sectioned for examination with 
confocal fluorescence microscopy. We observed intense staining of QRH*-Cy5.5 to surface 
(arrow) of SK-Hep1 human HCC cells but not for PEH*-Cy5.5 injected mouse tumors, Figure 
2.20(A-B). 
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Figure 2.20 Peptide binding to EGFR. Peptide binding results were validated on confocal fluorescence microscopy of tumor 
sections for (A) QRH*-Cy5.5 and (B) PEH*-Cy5.5 after imaging was completed and the mice were euthanized. Note intense 
staining of QRH*-Cy5.5 to surface (arrow) of SK-Hep1 human HCC cells. 
2.4 In vivo photoacoustic imaging of EGFR in HCC 
One of the limits of fluorescence imaging, discussed in Section 1.5, is lack of penetration depth 
due to light scattering. With photoacoustic imaging, high contrast in vivo imaging beneath the 
tumor surface could be acquired to confirm the penetration of peptide probe inside the tumor 
with systemic delivery. The results presented here were published in peer-reviewed journal 
article [135]. 
2.4.1 Photoacoustic as imaging modality 
Photoacoustic imaging is a non-invasive imaging modality which allows structural, functional 
and molecular imaging. Despite the fact that the PA effect was discovered by the legendary 
scientist Alexander G. Bell in the 1880s when experimenting with long-distance sound 
transmission [195], its application to biomedicine and microscopy was not achieved until a 
century later, in the 1980s [196, 197], after reliable and intense optical sources were developed. 
It has been intensively studied ever since [198]. In the past 20 years, photoacoustic imaging has 
become an emerging imaging modality that provides greater depth than optical methods and 
better resolution than ultrasound. Previous studies has reported the ability of hybrid plasmonic 
contrast agent gold nanotube (GNT) to achieve picomolar sensitivity compared to nanomolar 
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levels for conventional agents [199]. Moreover, indocyanine green (ICG) labeled with single 
walled carbon nanotubes (SWNT-ICG) can improve photoacoustic contrast by ~300-fold [84]. 
Compared to imaging methods for HCC diagnosis in the clinic, photoacoustic imaging has the 
merits of high resolution, fast turnover and low risk. The photoacoustic images in the current 
study were collected with a spatial resolution of 280 μm in all dimensions. By comparison, 
ultrasound at the same central frequency of 5 MHz without 3D data acquisition and image 
reconstruction can achieve 470 μm axial and 1-5 mm lateral resolution [200]. Nuclear imaging 
methods (PET and SPECT) have spatial resolution in the 1 to 2 mm range [73, 201]. Our in 
vivo images required a short image acquisition and reconstruction time (~2 min) than MRI or CT. 
With faster lasers and more efficient algorithms even real time image-guided surgery with a 
photoacoustic endoscope can be possible. This technique does not involve non-ionizing radiation, 
and can be more cost-effective and easier to use than MRI, PET, and SPECT. 
2.4.2 Working principle 
The method relies on the photoacoustic effect which describes conversion between light and 
acoustic waves due to absorption of electromagnetic waves and localized thermal excitation 
[202]. The principle of photoacoustic imaging is illustrated in Figure 2.21: short pulses of 
electromagnetic radiation, mostly short laser pulses, are used to illuminate a sample. The local 
absorption of the light is followed by rapid heating, which subsequently leads to thermal 
expansion. Finally, broadband acoustic waves are generated. By recording the outgoing 
ultrasonic waves with adequate ultrasonic transducers outside of the sample, the initial absorbed 
energy distribution can be recovered. Thus, photoacoustic imaging is a hybrid technique making 
use of optical absorption and ultrasonic wave propagation [203]. Thereby the advantages of both 
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techniques are combined: the high contrast of optical imaging and the high resolution of 
ultrasonic imaging. 
 
Figure 2.21 Working principle of photoacoustic imaging. Tissue is irradiated with a short laser pulse. Optical energy is absorbed 
by tisssue and converted into thermal energy. Optical absorption of short pulse of light leads to rapid thermal expansion of tissue 
and generation of acoustic (pressure) transients. The acoustic signal, recorded using ultrasound transducer, is usded to form an 
image. 
In this study, a major implementation of photoacoustic imaging principle called photoacoustic 
tomography (PAT) was employed. In PAT a semitransparent sample is illuminated by an 
expanded laser beam rather than a focused laser in PAM, thus illuminating the whole sample 
volume. The spatial varying local absorption leads to generation of ultrasonic waves which are 
recorded by an ultrasonic transducer. By moving the transducer around the sample, or by using 
an array of transducers, a dataset of pressure curves is acquired. By using adequate 
reconstruction algorithms the absorption of light within the sample (= image information) can be 
reconstructed. The resolution of PAT is determined by the duration of the excitation laser pulse 
and the bandwidth of the transducers, and is typically below 100µm. 
PAT has the unique capability of scaling its spatial resolution and imaging depth across both 
optical and ultrasonic dimensions [204]. In the optically diffusive region, the spatial resolution is 
acoustically defined. While a higher central frequency transducer provides a higher spatial 
resolution, the frequency-dependent acoustic attenuation (~1 dB/MHz/cm in muscle) limits the 
imaging depth. Low frequency (< 10 MHz) transducers are commonly used in PACT systems to 
provide an imaging depth greater than 1 cm. Above 10 cm, the imaging depth is also limited by 
 44 
 
light attenuation, which is a combined effect of optical absorption and scattering. With recent 
advances in optical wave-front engineering [205, 206], we expect the attenuation through optical 
scattering to be minimized, and PAT to eventually image tens of centimeters deep in tissue. By 
ultrasound measurement, a normal human liver is less than 16 cm in the midclavicular line [207]. 
All in vivo photoacoustic imaging in this study involved mouse subcutaneous HCC xenograft 
tumor. All tumors were imaged before the dimension reached 1cm. Thus low frequency (5 MHz) 
transducers were used to achieve ~1cm imaging depth. This imaging depth is sufficient for 
subcutaneous xenografts and potentially for orthotopic xenograft in mouse liver (<3cm in length 
and <1cm in thickness [208]). The most likely application in the clinic for PAT is intraoperative 
image guided surgery where the resection edge will be imaged for confirmation of negative 
margin. For that purpose, 1cm imaging depth would be sufficient. 
2.4.3 Near-infrared labeled photoacoustic imaging probe 
Compared to ultrasound, Photoacoustic (PA) imaging offers higher resolution, contrast and 
capability for targeted detection [209]. Previous photoacoustic imaging studies have used 
endogenous contrast from hemoglobin and melanin [210], and others have relied on the 
enhanced permeability and retention (EPR) effect [211, 212]. The EPR effect can be variable and 
produce false positives in highly vascular tissues [213] for nano-sized or smaller delivery agents 
[214]. These strategies are based on non-specific detection mechanisms. The use of a targeting 
moiety can improve tumor homing, increase signal, and improve contrast by tuning absorption to 
specific wavelengths [73].  
NIR dye labeled EGFR targeting peptide probe was used in the in vivo photoacoustic imaging 
study. Nanoparticles have 3-10 times higher extinction coefficient than organic dyes [215], and 
can absorb more energy from light per mass density. However, nanoparticles have not received 
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FDA approval for clinical imaging [216]. On the other hand, organic dyes have a benign toxicity 
profile [217] and pharmacokinetic characteristics are compatible with clinical translation. While 
prolonged circulation time of conventional nanoprobes may enhance targeted drug delivery [218, 
219], peptides may offer advantages for improved deep tumor penetration and accumulation with 
reduced biodistribution to non-target tissues [220, 221]. Nonetheless, metallic nanoparticle as 
optimized in vivo photoacoustic imaging contrast agent will be covered in Chapter 4, to push the 
envelope of clinical imaging for future applications. 
2.4.4 Photoacoustic imaging system 
We used a photoacoustic tomography system (Nexus128, Endra Inc.) that provided laser 
excitation at 7 ns pulses, 20 Hz repetition rate, 25 mJ/pulse, and wavelength range 680−950 nm. 
Ultrasound was collected by 128 unfocused 3 mm diameter transducers with 5 MHz center 
frequency arranged in a helical pattern in a hemispherical bowl filled with water, Figure 2.22 (A). 
A transparent imaging tray located above the transducers was used to contain anesthetized 
animals. The console also included data acquisition/reconstruction software, servo motors to 
rotate the bowl, and a temperature monitor. We optimized the imaging protocol to collect 120 
views with 10 pulses/view, covering an imaging volume of 25×25×25 mm3 with a voxel size of 
280 μm3. Each dataset required ∼2 min for acquisition and reconstruction. The animals were 
administered QRH*-Cy5.5 at 300 M in 250 L (75 nmol), and placed inside the tray with the 
subcutaneous tumor positioned inside a water-filled dimple to couple the ultrasound signal, 
Figure 2.22(B).  
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Figure 2.22 System schematic of photoacoustic imaging instrument (A) Laser pulses at l = 680 nm (green) are absorbed by the 
tumor to produce acoustic waves that are detected by 128 ultrasound transducers arranged in a helical pattern. Water between the 
imaging tray and transducer array provides acoustic coupling. (B) Photograph of live animal under anesthesia with tumor 
positioned inside a dimple in the center of the tray. C) The entire system is integrated and packaged inside a portable cart, 
reproduced with permission from http://www.endrainc.com. 
The entire imaging system was integrated and packaged inside a portable cart, Figure 2.22(C). 
The laser output 7ns 25mJ pulses at 20Hz in the tunable range of 680-950nm. The ultrasound 
transducers had 5MHz central frequency and 3mm in diameter. The acquisition operated at 
40MHz without multiplexing. This system can acquire image volumes of 25mm in each 
dimension with a spatial resolution of 280um. 
2.4.5 In vivo photoacoustic imaging of HCC 
At 6 weeks post inoculation, representative photoacoustic images collected with λex = 680 nm at 
0, 1, 3, 6, 12, and 24 hours after injection of 300 μM in 250 μL of QRH*-Cy5.5 i.v. were shown 
as maximum intensity projection (MIP) images at a mean (±SD) depth of 8.1±1.3 mm with range 
0 to 1.8 cm below the skin surface. At this time, the tumors had reached a mean (±SD) size of 
100±23 mm3 by US. For anatomic context, the field of view in photoacoustic imaging is 
2.5×2.5cm2 centered at the dimple (dashed circle) of imaging tray where the xenograft tumor 
(arrow) is placed, Figure 2.23(V). The tumors showed increased signal in a heterogeneous 
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pattern with visible blood vessels, Figure 2.23(A-F). Just after injection, there was minimal 
signal at the tumor. After 1 hr, tumor site as well as surrounding tissue lit up. After 3hrs, signal 
from surrounding normal area was cleared leaving contrast coming from the tumor alone. A 3D 
volume rendered image of the tumor at 3 hours post injection was shown (Video 2.5), Figure 
2.23(T). We can see the blood vessels feeding the tumor from behind. After that the peptide will 
be cleared from the system by 24 hrs post injection. Preliminary study (data not shown) 
confirmed wash out of either QRH-Cy5.5 or PEH-Cy5.5 from the animals’ system occurred by 
24 hrs post injection and no difference in signal intensity or pattern were associated to injection 
order.  
Imaging was repeated with PEH*-Cy5.5 and Cy5.5 alone (dye without peptide) 48 hours later in 
the same animals after the targeting peptide had cleared, Figure 2.23(G-L). We saw more signals 
inside the blood vessels rather than in the tumor. For additional control, images from HCC with 
free Cy5.5 alone, Figure 2.23(M-R), and the signal represented the enhanced permeability and 
retention effect at the tumor. Minimal signal was observed in the normal tissue after targeting 
peptide injection, Figure 2.23(S).  
The 3D image was reconstructed after completion of imaging using data acquired from all 128 
transducers at each view with a back-projection algorithm [199]. This algorithm corrected for 
pulse to pulse variations in laser intensity and small changes in temperature that affected the 
velocity of acoustic waves in water. The reconstructed raw data was analyzed using Osirix 6.5.2 
software (Pixmeo) to generate a maximum intensity projection (MIP) image, which was 
converted to a color map using Matlab (R2013a, ver 8.1, Mathworks) software. 3D visualization 
of the reconstructed photoacoustic signals was performed using Amira software (ver 5.4.3, FEI 
Corporation), including volume rendering technique (VRT) with specular shading and physics 
 48 
 
color map. The alpha value was set at 0.7 in order to reveal blood vessel structures underneath 
the tissue surface. 
The photoacoustic intensity from the tumor (target) was measured using a circular ROI with 
diameter determined from US (illustrated in Figure 2.23 (U) where the longer axis of the eclipse 
on ultrasound imaging was used as the diameter of circular ROI in photoacoustic imaging), and 
an adjacent annulus with area equal to that of the target ROI was used to measure background, 
indicated by white circles in Figure 2.23(C & I). 
 
 
Figure 2.23 Time course of PAI in HCC. Representative MIP images at depth of 1.8 cm were collected at 0, 1, 3, 6, 12 and 24 
hours after injection with (A-F) QRH*-Cy5.5 and G-L) PEH*-Cy5.5 are shown. In panel (C), inner circle represents regions of 
interest (ROI) used to measure signal from tumor, and adjacent annulus with equal area was used to measure background. (M-R) 
Images of tumor with injection of Cy5.5 alone (no peptide) at 0 to 24 hours post injection. (S) Image of normal area at 3 hours 
after QRH-Cy5.5 injection. (T) 3D reconstruction of tumor images. (U) Ultrasound image of subcutaneous tumor with dashed 
oval marking the tumor ROI. The longer axis of the oval was used as the circular ROI diameter in photoacoustic image 
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quantification. (V) Photograph of xenograft bearing mouse inside photoacoustic imaging tray with marked field (dashed circle) of 
view and tumor position (arrow) assisted with anatomic context. 
 
Video 2.5 3D PAI of QRH*-Cy5.5 on HCC 
 
 
Figure 2.24 Quantification of time course photoacoutic imaging. Images collected over time showed peak tumor QRH*-Cy5.5 
uptake at 3 hours after i.v. injection. T/B ratio of 2.25±0.25 was significantly greater than 1.31±0.36 for PEH*-Cy5.5, P = 
1.2×10-3 by paired t-test. Injection of Cy5.5 dye alone produced peak T/B ratio, 1.30±0.14, at 1 hour post injection at tumor site. 
T/B ratio of 1.22±0.14 at tumor site and 1.05±0.13 at adjacent normal tissue were observed at 3 hours respectively. Wash out of 
probe was observed within 24 hours. 
HCC tumors showed a higher T/B ratio for the EGFR peptide compared with that of the control 
peptide at each time point up to 24 hours. Tumor uptake of QRH*-Cy5.5 increased steadily after 
injection to a peak value at 3 hours, Figure 2.24. This peak time differed from the previous in 
vivo laparoscopic imaging and was due to the difference in sensitivity by different imaging 
instruments and different injection doses. The 3-hr peak time is clinically relevant as it would 
allow surgeons to inject the peptide probe at the beginning of surgery and check tumor margin 
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for fluorescent signal by peak time before finishing the surgery. It would eliminate the need to 
perform biopsy and histology staining which can take days before getting results. In the case 
where positive margins were found, the patient has to schedule and undergo a second surgery. 
The more than 2-fold increase in target-to-background ratio ensures that the tumor can be 
distinguished from surrounding normal tissue. The T/B ratio then decreased over time to near 
baseline by 24 hours. This time frame is significantly faster than most antibodies, which can take 
hours to home to the tumor and even longer to clear [222, 223]. Meanwhile, non-tumor exhibited 
minimal uptake. The HCC image with Cy5.5 alone (no peptide) showed a small effect of tumor 
permeability and retention [213, 224]. Injection of Cy5.5 dye alone produced peak T/B ratio, 
1.30±0.14, at 1 hour post injection at tumor site. 
 
Figure 2.25 Quantification of target-to-background ratio at 3 hrs post injection. Individual data points for T/B ratios at 3 hours are 
shown 
We measured a T/B ratio of 1.22±0.14 at the tumor site and 1.05±0.13 from adjacent normal 
tissue at 3 hours respectively. Peak T/B ratios for the EGFR and control peptides at 3 hours were 
plotted, Figure 2.25. Each individual mice are color coded to track the change in T/B ratio over 
six different time points (0h, 1h, 3h, 6h, 12h, 24h) post injection, Figure 2.26. 
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Figure 2.26 Target-to-background ratio of each individual mouse over time course. Each experiment mouse was color coded to 
track the change in T/B ratio over six different time points (0h, 1h, 3h, 6h, 12h, 24h) post injection. 
The typical shape of tumor xenografts in this study was oblate ellipsoid with almost equal 
dimensions parallel to skin surface but much shorter in depth beneath the skin (i.e. b < a ≈ c). 
Thus approximation of tumor area with circular ROI was adopted in PA signal intensity 
measurement for 2D MIP images. Two independent individuals each took three attempts to 
select ROI on ultrasound images and the average was taken to determine the diameter of circular 
ROI on photoacoustic images being quantified. Since ROIs on PA images were drawn at the 
center of field of view, its accuracy is dependent on whether the tumor was actually placed at the 
center of the dimple. Movement of the mice due to breathing could displace the tumor from the 
center by a couple millimeters. But this did not seem to affect background intensity value or the 
T/B ratio in any substantial way. In addition, 3D volumetric quantification of PA images could 
potentially give a more accurate intensity measurement if an algorithm capable of defining 
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arbitrary oblate ellipsoid as ROI and taking into account the illumination attenuation along tissue 
depth were available. 
2.4.6 Ex vivo validation of EGFR expression 
After in vivo PAI, ex vivo validation of EGFR binding by targeting peptide were performed on 
resected xenografts and the results were consistent with the in vivo findings. Resected tumor and 
normal liver (n = 24 mice) were formalin-fixed, paraffin embedded and cut in 10 m thick 
sections. Deparaffinization, rehydration and antigen unmasking was performed, as described 
previously. Blocking was performed with DAKO protein blocking agent (X0909, DAKO) for 1 
hour at RT. Sections were then incubated with 5 M QRH*-Cy5.5 in 2% BSA for 10 min at RT. 
The sections were washed 3 times with PBS and mounted with Prolong Gold reagent containing 
DAPI (Invitrogen). Confocal microscopy was performed using ex = 670 and 405 nm for Cy5.5 
and DAPI, respectively, at 63X magnification. Fluorescence intensities were measured from 3 
randomly positioned boxes with dimensions of 20×20 μm2. Regions that showed intensity 
saturation were avoided. 
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Figure 2.27 Immunostaining of HCC xenograft and normal liver with EGFR peptide. (A) Immunohistochemistry (IHC) with anti-
EGFR antibody shows increased reactivity to HCC. A nest of tumor cells with large irregular round nuclei (arrows) and 
infiltrating blood vessels lined with flattened endothelial cells (arrowhead) can be seen. (B) Immunofluorescence (IF) with 
QRH*-Cy5.5 shows binding to surface of HCC cells. Fluorescence intensities were measured from sets of 3 (dashed white) boxes 
with dimensions of 20×20 μm2. (C) Corresponding histology (H&E) of tumor. (D) IHC of normal mouse hepatocytes show few 
lightly stained cells (arrows) surrounding the central vein (arrowhead). (E) IF of normal mouse liver shows minimal signal. (F) 
Histology of normal mouse liver shows lobule with central vein (arrowhead) surrounded by radially aligned plates of hepatocytes. 
On immunohistochemistry (IHC), we observed strong staining of EGFR in HCC tumors, Figure 
2.27(A). On immunofluorescence (IF), strong signal from QRH*-Cy5.5 is seen on the surface of 
tumor cells, Figure 2.27(B). In normal mouse liver, a few lightly stained hepatocytes (arrow) can 
be seen surrounding the central vein (arrowhead) with IHC, Figure 2.27(D). Minimal signal from 
QRH*-Cy5.5 was seen in normal liver with IF, Figure 2.27(E). Corresponding histology (H&E) 
of tumor and normal is shown, Figure 2.27(C, F). 
 54 
 
 
Figure 2.28 Quantification of immunostaining in HCC xenograft with EGFR peptide. (A) Mean (±SD) fluorescence intensities 
for HCC (n=24 tumors) are significantly higher than that for normal liver (n =24), 27.8±11.5 versus 7.37±3.80 by 3.77-fold, 
P=3.4×10−10 by paired t-test. (B) ROC curve shows 92% sensitivity and 96% specificity with area under curve (AUC) of 0.97 for 
distinguishing HCC from normal liver using QRH*-Cy5.5. 
We found the mean fluorescence intensity from HCC to be significantly greater (P=3.4×10-10) 
than that of normal by 3.8-fold, Figure 2.28(A). The corresponding receiver operating 
characteristic (ROC) curve shows 92% sensitivity and 96% specificity for distinguishing HCC 
from normal liver with an area under the curve (AUC) = 0.97, Figure 2.28(B), indicating the 
probe would be an excellent diagnostic tool. Scattered dot plot was adopted to show the 
individual data points without overlapping. 
2.5 Discussions 
In this study, we used a version of Cy5.5 that has four additional hydrophilic –SO3H groups, 
Figure 2.1(A), to improve water solubility [135]. With the previous fluorophore, probe 
concentration of 100 M was used, which was adequate for topical administration to detect pre-
malignant disease in mouse colon [60]. In this study, we achieved a 3-fold greater concentration, 
and used systemic (intravenous injection through tail vein) administration to deliver the peptide 
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to a solid tumor. The improved probe solubility by sulfo-group modification on Cy5.5 dye label 
allowed for a smaller injection volume to deliver the desired dose. Because the peak absorption 
of Cy5.5 occurs below 700 nm, the imaging depth can be further improved with organic dyes, 
such as ICG and Licor IRDye800 [86, 225], that absorb at longer wavelengths and avoids 
hemoglobin absorbance and minimizes tissue scattering.  
We used human SK-Hep1 cells that overexpress EGFR to introduce HCC xenograft tumors. This 
technique may produce higher levels of EGFR expression and less heterogeneity than that found 
in sporadic human HCC [226]. In the future, we will use patient derived xenograft (PDX) models 
that include stroma and better reflect clinically relevant EGFR expression levels [227] and tumor 
microenvironment [228]. PDX models can also be effective for evaluating new drugs [229-231]. 
Both subcutaneous [228, 232, 233] and orthotopic [234] PDX models of HCC have been 
developed by other groups. Also, detection of multiple targets simultaneously may be needed to 
address the genetic diversity of HCC [235-237]. Our imaging system can use a broad range of 
wavelengths (680-950 nm). This spectrum covers the absorption peaks of many NIR dyes (Cy5.5, 
ICG, IRDye800) and nanoparticles (Au, SWNT and Co [75, 238, 239]). A panel of peptides 
labeled in spectrally distinct regions may be needed to achieve high detection sensitivity in the 
clinic. Adapting functionalized nanoparticles for excitation at different wavelengths would allow 
for multiplexed imaging to be performed [240]. 
2.6 Summary 
EGFR targeting peptide previously used to collect fluorescence images endoscopically from 
mouse colonic adenomas with topical administration was labeled with NIR dye Cy5.5 and 
validated in both colorectal dysplasia and HCC cell lines. The use of in vivo optical and 
photoacoustic imaging to visualize HCC xenograft tumors in living mice with a peptide specific 
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for EGFR was demonstrate. It was shown that specific binding to EGFR can also occur with 
systemic administration and tumor margins were clearly visible with on fluorescent laparoscope. 
Photoacoustic imaging at a depth down to 1.8 cm with low background confirmed peptide probe 
delivery deep inside tumor. We found peak uptake at 3 hours post injection and clearance by ~24 
hours. This time frame is significantly faster than most antibodies and applicable in clinical 
settings. 
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Chapter 3 Selection and validation of GPC3 targeting peptide for HCC  
3.1 GPC3 specific peptide as HCC targeting strategy 
In order to tackle the challenge of tumor heterogeneity, a second biomarker was investigated for 
in vivo HCC imaging with the potential for multiplexed detection. Since we are concerned about 
heterogeneity of human HCC patients, it makes sense to look for the best potential HCC 
biomarker from gene expression profiles of HCC patient specimens.  
3.1.1 Identification of GPC3 as HCC target 
We analyzed gene expression profiles of HBV-related HCC specimens from the GSE14520 and 
GSE44074 datasets [241-243]. GSE14520 provided the most comprehensive data. A total of n = 
213 pairs of HBV-related HCC and non-tumor specimens were analyzed using 22,268 probe-sets 
on an Affymetrix HT_U133A platform. We refined the data based on the following criteria: P-
value <1×10-40, average fold-change >2, and location on plasma membrane.  
 58 
 
 
Table 3.1 potential HCC targets. Glypican-3 (GPC3) is high, significant and specific expression in HCC extracellular membrane. 
Gene expression of GPC3 is elevated in HCC compared with non-tumor. A) Gene expression profiles from datasets GSE14520 
We used paired T-tests on log-transformed data, and obtained 1397 probe sets with P-value <1×10-40, of which 111 had GO terms 
indicating they appeared in plasma membrane, and were increased in tumors. Of these, GPC3 (red box) gave P-value = 1.1×10-70 
(5th best), and average fold-change of 29.261 (highest in tumors). We then analyzed log-transformed data for 8516 transcripts 
from dotted arrays measured in GEO series GSE44074, consisting of 34 HCC samples and 71 normal liver samples. A two-
sample T-test gave 549 genes with P < 0.001, of which 49 were increased in tumors and on plasma membrane. Of these GPC3 
gave both the largest fold-change and smallest p-value (4.5 fold increase, P = 3.5×10-15).  
We then analyzed log-transformed data for 8516 transcripts from dotted arrays measured in GEO 
series GSE44074, consisting of 34 HCC samples and 71 normal liver samples. A two-sample T-
test gave 549 genes with P < 0.001, of which 49 were expressed on plasma membrane (thus 
accessible for imaging) and were found to increase in tumors compared to normal. Of these, 
glypican-3 (GPC3) gave both the largest fold-change and smallest p-value (4.5 fold increase, P = 
3.5×10-15). A panel of promising cell surface targets, including CAP2, GPC3, and ROBO1, were 
overexpressed in HCC that can be developed for imaging, Table 3.1. GPC3 showed the largest 
fold-change of 29.26 between tumor and non-tumor with lowest P-value.  
Differences are reflected by the distribution of gene expression levels of individual tumors, 
Figure 3.1(A). Significant difference in GPC3 gene expression between HCC and non-tumor 
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specimens from n = 213 specimen pairs was found, P-value <0.001 by paired t-test, from 
GSE14520. Expression levels of normal and HCC liver samples were plotted with P-value 
<0.001 by 2-sample t-test, from GSE44074. The ROC curve for this data shows 87% sensitivity 
and 90% specificity with an area-under-the curve (AUC) of 0.92, Figure 3.1(B). These results 
show that GPC3 is a promising biomarker for HCC. GPC3 is high, significant and specific 
expression in HCC extracellular membrane. Gene expression of GPC3 is elevated in HCC 
compared with non-tumor. 
 
Figure 3.1 GPC3 overexpression in HCC. (A) Significant difference in GPC3 gene expression between HCC and non-tumor 
specimens from n = 213 specimen pairs was found, P-value <0.001 by paired t-test, from GSE14520. Expression levels of normal 
and HCC liver samples were plotted with P-value <0.001 by 2-sample t-test, from GSE44074. (B) ROC curve for GSE14520 
shows area under the curve (AUC) of 0.92 with 87% sensitivity and 90% specificity. 
3.1.2 Significance of GPC3 as HCC target 
Previous studies have established GPC3 as a promising HCC-specific target [244-246]. 
Glypicans (GPCs) are a family of heparin sulfate proteoglycans that anchor on the cell 
membrane with a glycosylphosphatidylinositol (GPI) linkage [247], Figure 3.2. This family 
consists of six members (GPC1-GPC6) in mammals. GPC3, a 70kDa protein, is composed of a 
core protein and two heparin sulfate chains [248]. GPC3 has been found to be significantly more 
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sensitive and specific for HCC than alphafetoprotein (AFP), a serum biomarker widely used in 
HCC surveillance [249, 250]. A significant increase in serum AFP level is detected in a 
considerable number of patients with chronic liver disease [251, 252] including 15%–58% of 
patients with chronic hepatitis and 11%–47% with cirrhosis [250]. On the other hand, GPC3 is a 
promising HCC-specific target on the cell surface [9, 21, 22, 253], whose expression is absent in 
normal adult tissues, but is significantly over-expressed in up to 80% of human HCC’s [9, 22, 
254]. A number of immunochemistry studies have found its expression is significantly elevated 
in HCC, but rarely detected in benign liver lesions cirrhosis, low-grade, and high-grade dysplasia 
[254-259]. Given the high expression in HCC, the usefulness of GPC3 as a target for both 
antibody and cell based immunotherapies have been explored [253, 260, 261].  
 
Figure 3.2 Structure of Glypican 3 on cell surface. Glypican 3 is anchored to the cell surface via a GPI linkage, has a conserved 
pattern of 14 cysteine residues, which contribute to intramolecular disulfide linkages, and displays GAG attachment sites 
predominantly near the membrane. Figure is adapted from Glypicans in Cancer 
(https://www.rndsystems.com/resources/artices/glypicansin-cancer). 
GPC3 participates in a variety of pathways related to HCC, such as Wnt [262, 263], Yap, BMP-7 
and FGF [264]. Through interactions with these signaling pathways, GPC3 can regulate HCC 
development, metastasis, and angiogenesis [247, 258, 265-267]. For example, overexpressed 
GPC3 is capable of binging Wnt [268] and facilitating Wnt/Frizzled interactions, which are 
believed to be vital in the progression of many cancers, including HCC [9, 265, 267]. Its 
expression profiling is an independent prognostic indicator in patients with HCC and is 
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correlated with the clinical malignant behavior of HCC [20, 269, 270]. Furthermore, it has been 
shown that mutations in GPC3 or knockdown of its function can inhibit HCC growth, reinforcing 
the important roles of GPC3 in HCC development [266, 271, 272]. 
An ideal marker should be able to differentiate malignant from normal and benign lesions with 
high sensitivity and specificity, and should be a marker in the early transition phase from 
premalignancy to malignancy [273-275]. HCC can develop from a variety of risk factors, 
including cirrhosis, HBV and HCV [276-278]. Many studies have shown that GPC3 is highly 
and specifically expressed in 70–100% cases of HCC, and could be used as a maker to 
differentiate HCC from benign liver tissues [279-282]. The sensitivity and specificity of a 
positive GPC3-staining for the diagnosis of HCC in small focal lesions was 77% and 96%, 
respectively, in resected cases, and 83% and 100%, respectively, for needle biopsies [283]. A 
diversity of targeting strategies, including antibody[284], antibody fragment [285], chimeric 
antigen receptor expressing T cells [286], have been explored for imaging and therapy of GPC3 
overexpressing HCC. The above evidence has led us to believe GPC3 has great potential as 
biomarker for HCC imaging. 
3.1.3 GPC3 targeting peptide selection 
GPC3 antibodies have been extensively incorporated in targeted probes for HCC imaging as they 
demonstrated superior targetability and specificity, with the limitation of long incubation time 
and high cost [287, 288]. ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody was able to delineate 
HCC patient derived orthotopic xenografts in PET, with tumor/liver ratios of 2.31-4.21 after 169 
hrs post injection [284]. In other studies, tumor to liver ratio reached nearly 32.5 on day 7 post-
injection of 89Zr-αGPC3 in orthotopic HCC xenografts [289]. Fragmented antibody can reduce 
the incubation time as well as blood half-life while retaining specificity of antibody. In the same 
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study, fragment of aGPC3 IgG1 was conjugated to 89Zr and visualized tumor on PET 4 hour after 
administration at contrast ratio of 23.3 [285].  
By comparison, small molecules such as peptide have the advantage of fast tumor uptake and 
clearance from the system as described in detail in Section 1.4. Thus, we selected a peptide 
sequence specific for GPC3 by biopanning phage display library against GPC3 core protein 
below. 
3.1.3.1 Phage display  
We adopted phage display [290] as our peptide selection strategy, Figure 3.3. Purified human 
GPC3 core protein (62 kDa, Sino Biological Inc.) expressed in human cells was immobilized to 
select peptide candidates that bind specifically to GPC3 protein. A library of M13 bacteriophages 
with >109 unique sequences was incubated with the GPC3 recombinant protein to identify high 
affinity binding interactions. After the washing step, unbound phages are removed and bound 
phages are eluded and isolated for identification. Amplification of purified phage clones 
generates enough phages for molecular characterization and application. 
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Figure 3.3 Peptide selection strategy: phage display. A schematic of affinity-based selection procedure adapted in phage display 
technology. The phage libraries can be screened against an immobilized target of interest, the unbound phages are washed away 
and the tightly bound phages are eluted, propagated and are used as probes against that target. Various events are illustrated in the 
phage affinity-based selection for probe development against a target. Figure was adapted from reference [291]. 
3.1.3.2 Library selection 
A linear phage display library was adopted for the selection of GPC3 specific peptide. There are 
two kinds of commercially available phage display libraries, linear and cyclic [292]. Linear 
library phages display either 7-mer (Ph.D.-7) or 12-mer (Ph.D.-12) random peptides fused to 
coat protein (pIII) of M13 phage, while cyclic library phages (Ph.D.-C7C) display randomized 7-
mer sequence flanked by a pair of cysteine residues which form a disulfide cross-link and 
cyclized peptides [293, 294]. These libraries have proven useful in identification of structural 
epitopes [295, 296] and leads for peptide-based therapeutics [297]. Here the C7C cyclic library 
was not adopted for the attempt of biopanning since it does not offer longer sequence and the 
disulfide-constrained peptide limits the 3D configurations the peptide is able to take.  
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Our first attempt to perform peptide selection in 7-mer library and the candidates was 
unsuccessful. Results are shown in Table 3.2, with decreasing copy numbers after 3rd and 4th 
rounds of panning. The majority of these sequences showed up in the panning outcomes for other 
targets, c-MET and FGFR2, indicating their amplification didn’t result from target specificity but 
rather intrinsic propensity to amplify more efficiently than other sequences. One possible reason 
for this outcome could be that 7-mer peptides were simply too short to form the 3D structure to 
recognize any epitope on the target protein. Thus a longer peptide library could potentially 
provide better targetability.  
 
Table 3.2 7-mer linear library panning results. Phage display results from screening 7-mer phage library against GPC3 core 
protein. Candidate sequences are arranged in descending order of 3rd and 4th round enrichment number. 
Our second attempt of biopanning performed with 12-mer linear library generated some 
interesting results. As shown in Table 3.3, the first candidate peptide has a stop codon at the 11th 
amino acid residue, which would have terminate the sequence at the 10th amino acid. However, 
the presence of the 12th amino acid, tyrosine (T), reveals that certain mechanism was allowing 
the translation to "read through" the stop codon and produce a 12-mer rather than a 10-mer 
peptide. A closer look at the sequencing result at nucleotide level is necessary to identify the 11th 
amino acid. 
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Table 3.3 12-mer library panning results. Four 12-mer peptide sequences were identified after 12-mer phage display against 
GPC3 core protein.  
3.1.3.3 Amber mutation 
The mechanism that suppressed the stop codon and allowed translation was amber mutation 
[298]. Amber mutations (UAG) were the first set of nonsense mutations discovered, isolated by 
Richard Epstein and Charles Steinberg and named after their friend Harris Bernstein (whose last 
name means "amber" in German). As can be seen in the codon chart in Figure 3.4(A), codon 
UAG is normally a stop codon. However, the presence of either supF or supE mutation, Figure 
3.4(B), in the anticodons of tRNA of tyrosine (UAC) or glutamine (CAG) can allow the 
translation of UAG stop codon into either Try or Gln respectively. 
 
Figure 3.4 Codon chart and amber suppressors. (A) UAG is one of the three Stop codons in the codon chart. (B) Anticodon of 
tRNA of tyrosine (UAC) or glutamine (CAG) can allow the translation of UAG stop codon into either Try or Gln respectively. 
Amber mutation restricted phage library survival inside only genetically specific host. Viruses 
with amber mutations are characterized by their ability to infect only certain strains of bacteria, 
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known as amber suppressors. These bacteria carry their own mutation that allows a recovery of 
function in the mutant viruses. For example, a mutation in the tRNA that recognizes the amber 
stop codon allows translation to "read through" the codon and produce full-length protein, 
thereby recovering the normal form of the protein and "suppressing" the amber mutation. Thus, 
amber mutants are an entire class of virus mutants that can grow in bacteria that contain amber 
suppressor mutations. 
 
Figure 3.5 Amber suppression in ALL* peptide sequencing result. The 11th amino acid in the DNA sequencing result is translated 
to glutamine (Q) in presence of supE (GlnV) of E. coli host strain ER2738 to suppress UAG stop codon. 
The specific E. coli host strain for phage amplification resulted in glutamine as the 11th amino 
acid in the 12-mer sequence. The recommended E. coli host strain ER2738 [299] (F´ proA+B+ 
lacIq Δ(lacZ)M15 zzf::Tn10(TetR)/fhuA2 glnV Δ(lac-proAB) thi-1 Δ(hsdS-mcrB)5.[rk– mk– 
McrBC–]) is a robust F+ strain with a rapid growth rate and is particularly well-suited for M13 
propagation. ER2738 is a recA+ strain. Commercially available F+ strains can be substituted for 
ER2738, but any strain used should be supE (GlnV) in order to suppress amber (UAG) stop 
codons within the library with glutamine. Therefore, the 11th amino acid is translated as a 
glutamine, rather than tyrosine, as shown in the sequencing result of ALL* peptide, Figure 3.5. 
The nature of phage protein translation provided essential confirmation for the success 
suppression of amber stop codon when direct evidence from fusion protein sequencing is 
unattainable. The peptides fused coat protein (ALL*-pIII) is translated from the N-terminus 
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where the 12-mer peptide ALL* precedes pIII. Since pIII is essential for the phages’ survival, 
failure of amber suppressing at 11th amino acid would preclude pIII translation and consequently 
eliminate the existence of ALL* 12-mer peptide carrying phages. In other word, no ALL* 
phages would have survived to be DNA sequenced in the first place. Admittedly, direct 
sequencing of fusion protein would ultimately confirm the actual expression of 12-mer peptide 
sequence. However, isolating phage proteins from those of E. coli and purifying the few copies 
of fusion protein from the thousands of native coat proteins on the phage proved extremely 
challenging, if at all possible, without extensive protein characterization facilities and experience. 
Thus it is beyond the scope of this thesis to pursue.  
3.2 Validation in human tissue with targeting phage 
ALL*-Cy5.5 phages were first Cy5.5 labeled to verify peptide specificity for GPC3 expression 
on human HCC specimens before intensive time (1~2 months) and resources were invested in 
the synthesis of the Cy5.5 labeled 12-mer peptide for extensive in vitro and ex vivo validations.  
3.2.1 Labeling phage with NIR dye 
Cy5.5 labeling on ALL*-Cy5.5 phages can be done quickly and allowed GPC3 specific binding 
on human HCC tissue to be visualized when Cy5.5 labeled wildtype phages served as control for 
non-specific binding. After isolation and identification of candidate phage displaying targeting 
peptide as N-terminal pIII fusions, amplified and purified phages were labeled with near-infrared 
dye Cy5.5 as imaging agent to validate binding on human HCC tissue. Specifically, Cy5.5 NHS 
ester solution was prepared at 5 mg/ml in 0.1M bicarbonate buffer, pH8.3 (conjugation buffer). 
In parallel, an aliquot of 0.5x1013 plaque-forming units (pfu) of phages was precipitated with 
standard polyethylene glycol 8000 (PEG 8000, Sigma) and NaCl solution (20% PEG, 2.5M NaCl) 
and subsequently re-suspended in 200 uL of conjugation buffer in microfuge tubes. Phage 
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suspensions were incubated in the dark on a rotator for 2 hours at room temperature with 20 μL 
of Cy5.5 NHS ester solution. Following incubation, phages were precipitated (12k rpm for 
10min) 3 times with 200uL of PEG and NaCl. The final pellet was dissolved in 200uL 1X TBS, 
pH7.5. To confirm the success of the conjugation the UV-absorbance was checked at 673 nm. 
The schematic of Cy5.5 labeled ALL* and wildtype (WT)-phages are shown in Figure 3.6(A) 
and Figure 3.6(B) respectively. 
 
Figure 3.6 NIR dye labeled GPC3 targeting phages. Schematic of (A) ALL* and (B) wildtype phages labeled with Cy5.5 dye. 
3.2.2 Binding of GPC3 targeting phages and antibody to human HCC 
Cy5.5 labeled ALL*-Cy5.5 phages and wildtype phages were applied to paraffin embedded 
human HCC and normal liver specimens respectively to perform microscopic validation of 
peptide binding to GPC3 overexpression in HCC. Specimens of human HCC and normal liver 
specimens were obtained from biopsy during HCC resection surgery. Deparaffinization, and 
antigen retrieval was performed as previously described. Sections were incubated with ALL* 
peptide displaying phages labeled with NIR dye Cy5.5 (4 μM) in 1 × TBS for 10 min at RT, or 
overnight at 4 °C with 1:200 dilution of primary monoclonal rabbit anti-GPC3 antibody (Abcam 
Inc, SP86). The antibody stained sections were washed three times with PBS and incubated with 
1:500 dilution of Alexa Fluor 488-labeled secondary goat anti-rabbit antibody (Invitrogen) for 1 
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h at RT. The sections were then washed once with PBS, and mounted with ProLong Gold 
reagent containing DAPI (Invitrogen). Confocal microscopy (Leica TCS SP5 Microsystems) was 
performed with a 20× objective. The mean fluorescence intensities from three boxes (dimensions 
of 20 × 20 μm2) located within HCC, cirrhosis and normal portion of each specimen were 
measured respectively. Regions that showed intensity saturation were avoided. Sections were 
processed for routine histology (H&E) that was reviewed by a hepatobiliary pathologist. 
 
Figure 3.7 Immunofluorescence of Cy5.5 labeled phages and antibody on human HCC tissue. We observed specific binding of 
(A) ALL*-Cy5.5 phages and (B) anti-GPC3-AF488 antibody to HCC over cirrhosis (arrow) in human tissue on 
immunofluorescence. (C) No staining was observed from Cy5.5-labeled wild-type phages on human HCC tissue. 
We found increased cell surface staining of ALL*-Cy5.5 phages compared with Cy5.5 labeled 
wildtype phages to HCC versus surrounding cirrhotic tissue (arrow), Figure 3.7(A & C). We 
performed immunofluorescence with a known antibody to validate over expression of GPC3 in 
mouse colonic dysplasia, Figure 3.7(B). Minimal staining was observed for either peptide with 
normal human liver tissue, Figure 3.8(A-B). Fluorescence intensities (mean±SD) measured for 
HCC, cirrhosis and normal (n=10) were 90.69 ± 11.22, 41.01 ± 12.56 and 8.05 ± 2.19, 
respectively, *P<0.01 by unpaired t-tests, Figure 3.8(C). These results indicate ALL*-Cy5.5 
phages can specifically bind to overexpressed GPC3 in human HCC, creating contrast against 
normal and cirrhotic tissue. 
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Figure 3.8 Immunofluorescence of Cy5.5 labeled phages and antibody on normal human liver. (A) ALL*-Cy5.5 phages or (B) 
AF488-labeled anti-GPC3 antibody showed minimal immunofluorescence was seen on normal human liver. (C) Fluorescence 
intensities (mean±SD) measured for HCC (n=10), cirrhosis and normal were 90.69 ± 11.22, 41.01 ± 12.56 and 8.05 ± 2.19, 
respectively, *P<0.01 by unpaired t-tests. 
3.2.3 GPC3 expression in human HCC on immunohistochemistry 
 
Figure 3.9 IF and IHC on human HCC tissue with antibody. (A) Increased expression of GPC3 in human HCC specimens 
compared to liver cirrhosis was confirmed on immunohistochemistry using anti-GPC3 antibody (GαR), scale bar 100 μm. (B) 
minimal reactivity was seen on immunohistochemistry of normal human liver. 
Immunohistochemistry was performed as described in Section 2.2.1.4, with a known GPC3 
antibody (1:100, Abcam Inc, SP86), to provide additional confirmation on overexpression of 
GPC3 in human HCC, Figure 3.9(A). Normal liver section with the same primary antibody 
(control) shows minimal reactivity, Figure 3.9(B). Controls were prepared using secondary 
antibody, Elite Vectastain ABC reagent, and DAB (without primary anti-GPC3 antibody). Serial 
sections were processed for histology (H&E). Corresponding histology (H&E) of human HCC 
and normal liver tissue is shown, Figure 3.10 (A-B). 
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Figure 3.10 H&E histology of human HCC and normal liver tissue. (A) Corresponding histology (H&E) for HCC and cirrhosis is 
shown. (B) Corresponding histology (H&E) for normal liver is shown. 
3.3 Peptide synthesis and labeling 
Despite their ability to distinguish HCC on human specimens, phages cannot be clinically 
translated due to their biohazard and health risks to patients. The GPC3 targeting 12-mer peptide 
sequence had to be synthesized and labeled with NIR dye for further in vitro and ex vivo 
validations. On the phages, the displayed peptide (12-mer) is expressed at the N-terminus of pIII, 
i.e., the first residue of the mature protein is the first randomized position. The peptide is 
followed by a short spacer GGGS (Gly-Gly-Gly-Ser) and then the wildtype pIII sequence, Figure 
3.6. Therefore, a linker sequence, GGGSK, was designed in synthesized peptide in order to 
replicate the chemical environment of targeting sequence displayed on the phages. The lysine (K) 
residue was placed at the C-terminal of the sequence to conjugate with Cy5.5 NHS (N-
hydroxysuccinimide) ester through the amine group. The long carbon chain on lysine’s R-group 
offset the dye molecule way from the targeting sequence to minimize steric hindrance during 
binding. Cy5.5 was chosen for its high quantum yield and photostability [130] as discussed in 
more detail in Section 2.1.3.  
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3.3.1 Synthesis and labeling procedures 
We synthesized Cy5.5-labeled peptides using standard Fmoc-mediated solid-phase synthesis as 
previously described in Section 2.1.3. The resulting labeled GPC3 targeting peptide 
(ALLANHEELFQT) structure is shown in Figure 3.11(A). A scrambled peptide sequence 
(QLELTFHANLEA) with the same amino acid components is also and synthesized as control, 
hereafter QLE*-Cy5.5, Figure 3.11(B).  
 
Figure 3.11 Chemical structure of 12mer targeting peptide and scrambled control. (A) Chemical structure of 12 amino acid 
peptide ALLANHEELFQT (black) with GGGSK linker (blue) and Cy5.5 fluorophore (red), hereafter ALL*-Cy5.5. (B) 
Scrambled control peptide QLELTFHANLEA (black), hereafter QLE*-Cy5.5. 
From 3D space filing structure simulations, both the overall shape and local chemical 
environment are different after scrambling the targeting peptide, Figure 3.12(A-B). This could 
account for the loss in targeting ability of the scrambled peptide and serve as experiment control 
for non-specific binding. The N-terminals of peptides where the 12-mer sequences begin are 
denoted with arrow heads while arrows mark the positions of Cy5.5 labels. 
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Figure 3.12 3D space filing structures of both (A) targeting and (B) scrambled control peptides with Cy5.5 label. 3D space filing 
structures of peptides show site for attachment of Cy5.5 label (arrows). 12-mer sequences begins at N-terminus (arrowheads). 
Both the overall shapes and local chemical environments are different in the two probes. Color code: grey - C; white - H; red - O; 
blue - N; yellow - S. 
3.3.2 Spectral characterization 
 
Figure 3.13 Absorbance and fluorescence spectra of labeled 12-mer peptides. (A) Absorbance spectra of Cy5.5-labeled peptides 
shows peak at λex = 677 nm. (B) Maximum fluorescence emission is seen at λem = 708 nm for both peptides. 
After NIR dye labeling, spectral characterization confirmed peak absorption/emission 
wavelengths and molecular weight of peptide probes. Spectra were collected 100 μM 
concentration with a UV-Vis spectrophotometer in the 500-900 nm range (NanoDrop 2000, 
Thermo Scientific). Fluorescence emission from a 5 µM peptide solution diluted in PBS was 
collected with a fiber coupled spectrophotometer (Ocean Optics) using a diode-pumped solid 
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state laser (Technica Laser Inc) with λex=671 nm. The spectra were plotted with Origin 6.1 
software (OriginLab Corp). The absorbance spectra of ALL*-Cy5.5 and QLE*-Cy5.5 at 10 μM 
in PBS showed a maximum at 677 nm, Figure 3.13(A). The fluorescence spectra of ALL*-Cy5.5 
and QLE*-Cy5.5 at 10 µM concentration in PBS with λex = 671 nm excitation revealed a peak 
emission at 708 nm, Figure 3.13(B). We purified the Cy5.5-labeled peptides to >96% on HPLC, 
and measured an experimental mass-to-charge (m/z) ratio on mass spectrometry of 2335.22 for 
both QRH*-Cy5.5 and PEH*-Cy5.5 that agreed with expected molecular weight values, Figure 
3.14(A-B). 
 
Figure 3.14 Mass spectrometry of Cy5.5-labeled peptides. An experimental mass-to-charge (m/z) ratio was measured for (A) 
ALL*-Cy5.5 and (B) QLE*-Cy5.5 of 2335.22 (with one C-13), which agrees with the expected value of 2335.23 for both 
peptides. 
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3.4 In vitro validation of peptide targetability 
As Section 3.2 demonstrated, Cy5.5 labeled ALL* peptide carrying phages proved to bind 
specifically to GPC3 overexpression in HCC specimens. This prompted us to validate the 
performance of Cy5.5 labeled ALL* peptide, All*-Cy5.5 in vitro. To see if ALL*-Cy5.5 probe 
actually binds to GPC3 on surface of human HCC cell lines were first conducted in vitro before 
ex vivo validation in HCC mouse model was undertaken.  
3.4.1 GPC3 expression levels in HCC cell lines 
Human HCC cells Hep3B, HepG2, and SK-Hep1 were purchased from the ATCC (Manassas, 
VA) and cultured in Eagle's Minimum Essential Medium (EMEM). All cells were cultured at 
37ºC in 5% CO2, and supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. Cell lysates of three cell lines were separated into plasma membrane 
protein fraction and cytosolic protein fraction respectively using a membrane protein extraction 
kit (K268-50, Biovision) and protein concentrations were determined by BCA protein assay kit 
(23225, Thermo Fisher Scientific) before loading for Western blotting. Western blot was 
performed using a 1:10000 dilution of primary monoclonal rabbit anti-GPC3 antibody (Abcam 
Inc., EPR5547) per manufacturer instructions. Loading was controlled with a 1:500 dilution of 
monoclonal mouse anti-β-tubulin (#32-2600, Invitrogen). Western blot showed difference in 
expression of GPC3 for Hep3B, HepG2 and SK-Hep1, Figure 3.15. The differential GPC3 
expression levels in these three HCC cell lines served as the testing field for the specificity of 
GPC3 binding by peptide probe. Binding intensity in each cell line was expected to correlate 
with GPC3 abundance and was measured through the fluorescence signal on immunofluorescent 
imaging. 
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Figure 3.15 GPC3 expression levels in HCC cell lines. Western blot showed GPC3 (molecular weight = 66 kDa) expression 
levels for HCC cells in cytoplasm (C) and plasma membrane (M). Loading control was performed with tubulin (50 kDa). 
3.4.2 GPC3 specific binding on HCC cell lines 
Immunofluorescence staining with both peptide probes and GPC3 antibody was performed as 
described in Section 2.2.2.2. Hep3B, HepG2, and SK-Hep1 and incubated with 5 µM ALL*-
Cy5.5 and QLE*-Cy5.5 for 30 min at 4ºC respectively. For antibody staining, Cells were 
incubated with 1:200 dilution of anti-GPC3 antibody overnight at 4ºC. 
Peptide binding to the plasma membrane (arrows) was observed on confocal microscopy and 
significantly greater fluorescence intensity for ALL*-Cy5.5 than QLE*-Cy5.5 to Hep3B, HepG2 
and SK-Hep1 cells was found, Figure 3.16(A-F). An AF488-labeled anti-GPC3 antibody also 
showed significantly greater signal than the control peptide, Figure 3.16(G-I). 
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Figure 3.16 Immunofluorescence on HCC cell lines. On confocal microscopy, we observed strong fluorescence intensity from 
ALL*-Cy5.5 binding to the surface (arrow) of (A) Hep3B and (B) HepG2 human HCC cells, and minimal signal with (C) SK-
Hep1 cells. (D-F) Minimal signal is observed with the scrambled control peptide QLE*-Cy5.5 for all cells. Strong binding (arrow) 
is also observed with AF488-labeled anti-GPC3 antibody used as a positive control for (G) Hep3B and (H) HepG2 and minimal 
signal with (I) SK-Hep1. 
Quantified results were summarized in Figure 3.17. The intensity difference for Hep3B vs SK-
Hep1 was significantly larger for ALL* than for the same difference for QLE* (P=3.8×10-10, 8.2-
fold larger), and the HepG2 vs SK-Hep1 difference was also significantly larger (P=4.6×10-5, 
3.3-fold larger). The Hep3B vs SK-Hep1 difference was also larger for antibody than QLE 
(P=2.3×10-8, 6.0-fold larger). Fluorescence intensities from 3 independent images were 
quantified using custom Matlab (Mathworks) software. Intensity was measured with 6 replicates 
per condition and fitted to an ANOVA model with terms for 9 means to log-transformed data. 
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Figure 3.17 Quantification of immunofluorescent staining on HCC cell lines. The intensity difference for Hep3B vs SK-Hep1 
was significantly larger for ALL* than for the same difference for QLE* (P=3.8×10-10, 8.2-fold larger), and the HepG2 vs SK-
Hep1 difference was also significantly larger (P=4.6×10-5, 3.3-fold larger). The Hep3B vs SK-Hep1 difference was also larger for 
antibody than QLE (P=2.3×10-8, 6.0-fold larger). Intensity was measured with 6 replicates per condition and fitted to an ANOVA 
model with terms for 9 means to log-transformed data. 
3.4.3 siRNA knockdown of GPC3 and co-localization 
Short interfering RNA (siRNA) knockdown is a technology that degrades target messenger RNA 
to ‘knock down’ the production of a protein in the cell. The combination of siRNA-treated cells 
and a specific antibody will result in a significant drop in signal compared to an untreated sample 
by Western blot. This rigorous validation strategy for peptide target specificity by incorporating 
negative control is an essential part of experimental design described below.  
We examined GPC3 knockdown in Hep3B cells using ON-TARGETplus human GPC3 siRNA 
(#L-011868-00-0005), ON-TARGETplus Non-targeting pool (#D-001810-10-05), and 
DharmaFECT transfection reagents (Thermo Scientific). Briefly, cells were seeded in 6-well 
culture plates at 30% confluence EMEM medium supplemented with 10% fetal bovine serum 
without antibiotics. The next day, cells were transfected with siRNA at a final concentration of 5 
µM/L using oligofectamine (Thermo Scientific). Knockdown of GPC3 was confirmed by 
western blot. Cells were first washed in PBS and then lysed in RIPA buffer containing 1% 
Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml phenylmethylsulfonylfluoride, 
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and 1 mM sodium orthovanadate. Aliquots were placed on ice for 30 min and centrifuged at 
14,000 RPM for 10 min. Protein aliquots were denatured in loading buffer at 95ºC for 5 min, 
separated on SDS-polyacrylamide gels (SDS-PAGE), and transferred onto PVDF membranes. 
The membrane was blocked with blocking buffer (5% skim milk in 0.1% PBST) for 30 min. The 
membranes were incubated with anti-GPC3 primary antibody (1:10000 dilution, rabbit 
monoclonal, Abcam Inc., EPR5547) at 4ºC overnight. After washing 5X with PBST and 5X with 
PBS, the membrane was incubated for 1 hour in peroxidase-conjugated secondary antibody 
(1:5000 dilution; GE Healthcare), and were developed using the western blot chemiluminescent 
substrate (GE Healthcare). The luminescent signal was detected by exposure to X-ray film 
(Denville Scientific). Western blot shows effective GPC3 knockdown, Figure 3.18. 
 
Figure 3.18 Western Blot of GPC3 knockdown in Hep3B cells. Western blot shows GPC3 expression level in Hep3B cells 
transfected with siGPC3 targeting siRNA and siCL non-targeting siGPC3 (control). 
We performed siRNA knockdown experiments with Hep3B cells to validate specific binding of 
ALL*-Cy5.5 to GPC3. On confocal microscopy, ALL*-Cy5.5 (red) and AF488-labeled anti-
GPC3 antibody (green) bound strongly to the surface (arrows) of control Hep3B cells 
(transfected with siCL, non-targeting siRNA), Figure 3.19(A-B). Minimal binding was observed 
when staining with scrambled control peptide QLE*-Cy5.5, Figure 3.19(C). Significantly 
reduced fluorescence intensities were observed for Hep3B knockdown cells (transfected with 
siGPC3, targeting siRNA), Figure 3.19(D-E). QLE*-Cy5.5 scrambled peptide stains negative on 
knocked down cells, Figure 3.19(F).  
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Figure 3.19 IF of GPC3 knockdown. (A) ALL*-Cy5.5 (54.3±6.0) and B) AF488-labeled anti-GPC3 (37.7±7.5) binds 
significantly greater to the surface (arrows) of siCL treated Hep3B control cells compared to D,E) siGPC3 knockdown cells 
(14.7±1.5 and 8.8±2.7 respectively). (C, F) scrambled control peptide QLe*-Cy5.5 doesn’t bind to either siCL or siGPC3 treated 
Hep3B cells. 
Fluorescence intensity was reduced to 27% in cells knocked down in GPC3 expression with 
peptide and 23% with antibody, as quantified in Figure 3.20. The siCL vs siGPC3 difference was 
7.4 times bigger for ALL than the same difference for QLE (P=7.8×10-5), and the difference for 
antibody was 8.9 times bigger than for QLE (P=2.5×10-5), by ANOVA on log-transformed data. 
Results were an average of 6 images collected independently. 
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Figure 3.20 Quantification of GPC3 knockdown. Quantified fluorescence intensities. The siCL vs siGPC3 difference was 7.4 
times bigger for ALL than the same difference for QLE (P=7.8×10-5), and the difference for antibody was 8.9 times bigger than 
for QLE (P=2.5×10-5), by ANOVA on log-transformed data. Results were an average of 6 images collected independently. 
3.4.4 Competition for peptide binding 
To prove the receptor specificity of targeting peptide, competition assay between fluorochrome 
labeled and unlabeled peptide are generally performed. Particularly for this study, specific 
binding of ALL*-Cy5.5 to HT29 cells was validated on competitive inhibition with unlabeled 
ALL* peptide. ~7500 Hep3B cells were grown to ~70% confluence on cover slips in triplicate. 
Unlabeled ALL* peptide at 0, 50, 100, 150, 250 and 500 µM were added and incubated with the 
cells for 30 min at 4ºC. The cells were washed 3X with PBS, and further incubated with 2 µM of 
ALL*-Cy5.5 for another 30 min at 4ºC. The cells were washed 3X with PBS and fixed with 4% 
PFA for 10 min. The cells were washed with PBS and mounted with ProLong Gold reagent 
containing DAPI (Invitrogen). Confocal fluorescence images were collected at each 
concentration, and intensities from 3 independent images were quantified using custom Matlab 
(Mathworks) software. 
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Figure 3.21 In vitro competition confirms specificity of targeting peptide. Fluorescence intensities (mean ± SD) showed a 
significant decrease in ALL*-Cy5.5 binding to Hep3B cells with addition of unlabeled ALL* at concentrations of 50 µM and 
higher. P values by ANOVA model with terms for 11 means were shown above each result. Addition of unlabeled QLE* 
(scrambled control) peptide showed no change. Each result was an average of 6 independent measurements. 
Binding occurred with the peptide rather than the fluorophore was confirmed by adding 
unlabeled ALL* to compete with ALL*-Cy5.5 to Hep3B cells. We found the fluorescence 
intensities decreased significantly in a concentration dependent manner, Figure 3.21. 
Fluorescence intensities (mean ± SD) showed a significant decrease in ALL*-Cy5.5 binding to 
Hep3B cells with addition of unlabeled ALL* at concentrations of 50 µM and higher. P values 
by ANOVA model with terms for 11 means were shown above each result. Addition of 
unlabeled QLE* (scrambled control) peptide showed no change. Each result was an average of 6 
independent measurements. 
3.4.5 Characterization of peptide binding kinetics 
We measured the apparent dissociation constant of the GPC3 peptide to Hep3B cells as an 
assessment of binding affinity. ALL*-Cy5.5 was serially diluted in PBS at concentrations of 0, 5, 
10, 25, 50, 75, 100, 125, 150 and 200 nM. Approximately 106 Hep3B cells were incubated with 
ALL*-Cy5.5 at 4 °C for 1 h and washed with cold PBS. The mean fluorescence intensities were 
measured with flow cytometry (BD LSR Fortessa, BD Biosciences). The equilibrium 
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dissociation constant k
d
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 was calculated by performing a least-squares fit of the data to the 
nonlinear equation I = (I
0
 + I
max
k
a
[X]) / (I
0
 + k
a
[X]). I
0
 and I
max
 denoted the initial and maximum 
fluorescence intensities, corresponding to no peptide and at saturation, respectively, and [X] 
represents the concentration of the bound peptide. Graphpad prism (v. 6.02, Graphpad Software 
Inc.) analysis software was used to plot data and fit curve to calculate k
d
 and k
a
. 
The apparent association time constant of the peptide to Hep3B cells was measured to assess 
binding kinetics. Hep3B cells were grown to ∼80% confluence in 10 cm dishes, and detached 
with PBS-based cell dissociation buffer (Invitrogen). Approximately 106 cells were incubated 
with 5 μM ALL*-Cy5.5 at 4 °C for various time intervals ranging from 0 to 40 min. The cells 
were centrifuged, washed with cold PBS, and fixed with 4% PFA. Flow cytometry was 
performed, and the median fluorescence intensity (y) was ratioed with that of Hep3B cells 
without addition of peptide at different time points (t) using Flowjo (v. 10.1r5, FlowJo, LLC) 
software. The rate constant k was calculated by fitting the data to a first-order kinetics model, y(t) 
= I
max
[1 − exp(−kt)], where I
max
 = maximum value, using OriginPro (v. 9.2.214 academic, 
OriginLab Corp.) and Graphpad Prism 5.0 software.  
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Figure 3.22 Apparent dissociation constant and association time constant. (A) apparent dissociation constant kd = 71 nM, R
2= 
0.97, and (B) apparent association time constant k = 0.11 min-1 (i.e. 1/k=9.09 min), R2= 0.90, for binding of ALL*-Cy5.5 to 
Hep3B cells using flow cytometry. Results for each measurement were representative of 3 independent experiments. 
We measured the binding parameters of ALL*-Cy5.5 to Hep3B cells using flow cytometry, and 
found an apparent dissociation constant of kd = 71.28 nM, R
2 = 0.97, Figure 3.22(A), and an 
apparent association time constant of k = 0.11 min-1 (i.e. 1/k=9.09 min), R2 = 0.90, to support 
rapid binding with systemic administration, Figure 3.22(B). The first-order kinetics model rather 
than a linear regression model was adopted for fitting the association kinetics data because of the 
restraint that the fitted curve must pass data point (0,0) (R2=0.33 for linear regression fitting). 
3.5 Ex vivo validation of peptide targetability 
After in vitro validation and binding kinetics characterization on HCC cells overexpressing 
GPC3, ex vivo binding assays with in an animal HCC model can challenge specificity of peptide 
probe with non-HCC cells in the harvested xenograft tumor and provide evidence needed to 
justify in vivo imaging applications of peptide probe. 
 85 
 
3.5.1 HCC xenograft mouse model 
Cells of the human hepatocellular (HCC) cell lines Hep3B and SK-Hep1 (American Type 
Culture Collection, Manassas, VA) were grown in Eagle's Minimum Essential Medium (EMEM) 
containing 5% fetal bovine serum and routinely cultured in a humidified incubator with 5% CO2 
at 37ºC. Hep3B cells were diluted in growth factor reduced (GFR) Matrigel Matrix (Corning), 
and injected into one flank of female (to avoid male dominance within a cage) nude athymic 
mice (nu/nu, Jackson Laboratory, n=26) at 4 to 6 weeks of age with weight between 20 to 25 
grams. Control group mice (n=26) were injected with SK-Hep1 cells instead. 5×106 cells were 
implanted per mouse. Anesthesia was induced and maintained via a nose cone with inhaled 
isoflurane mixed with oxygen at a concentration of 2 to 4% at a flow rate of 0.5 L/min for all in 
vivo animal experiments, Figure 4.8. Mice were fed alfalfa-free diet (TD.97184, Harlan Teklad, 
WI) to prevent auto fluorescence from chlorophyll in food. 
 
Figure 3.23 Hep3B xenograft mouse model. Subcutanesou xenograft (arrow) was implanted from human HCC cell line, Hep3B, 
on the flank of nude mouse. 
3.5.2 Ultrasound imaging 
Tumor size was monitored weekly for 6 weeks with ultrasound imaging as described in Section 
2.3.2. Representative images are shown 2 weeks following cancer cell injection with ultrasound 
(US), Figure 3.24(A), and color Doppler imaging reveals blood vessels around the tumor, Figure 
3.24(B). 
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Figure 3.24 Ultrasound imaging of HCC xenograft. Representative images of subcutaneous HCC tumor (arrow) at 2 weeks post-
inoculation are shown with A) ultrasound (US) and color Doppler ultrasound showing flow of blood around the tumor (Red: out 
of the page; Blue: into the page).  
3.5.3 MRI imaging 
Tumor size was confirmed with Magnetic resonance imaging (MRI) as described in Section 
2.3.2. Figure 3.25(A) showed the location and size of xenograft. Segmented MR images were 
reconstructed into a 3D rendering image in Figure 3.25(B). Tumor growth increased 
exponentially after 2 weeks of implantation when average diameter of xenograft reached 5mm. A 
peak tumor volume (±SD) of 3584±869 mm3 was found at the end point (week 6) of tumor 
monitoring on US, Figure 3.25(C). A correlation of r = 0.99 was found between tumor size on 
US and MRI, Figure 3.25(D). 
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Figure 3.25 MR imaging of HCC xenograft tumor growth monitoring. (A) MRI (T1 weighted contrast-enhanced) image of HCC 
xenograft tumor (arrow). (B) Segmentation of 3D rendering (reconstructed from a series of 25 MR images) of MR imaging to 
highlight relative size and position of HCC tumor and spinal cord. (C) Mean (±SD) dimensions for n=10 tumors from US and 
MRI images from post inoculation weeks 1-6 are shown. (D) Correlation between MRI and ultrasound tumor volume 
measurements was found to be r=0.99 (linear regression with log log plot). 
3.5.4 Ex vivo fluorescence imaging of mouse HCC xenograft  
We collected confocal images to perform microscopic validation of peptide binding ex vivo. 
Specimens of HCC xenograft in nude mice were resected at 2 week post inoculation, paraffin 
embedded and cut into 10 μm sections. Sections were processed for immunofluorescent staining 
as described in Section 2.2.1.3 with either 5 µM of ALL*-Cy5.5 and QLE*-Cy5.5 for 30 min at 
4ºC respectively or with 1:200 dilution of primary rabbit anti-human anti-GPC3 antibody 
(Abcam Inc, SP86) and AF488-labeled secondary antibody. Adjacent sections were processed 
for histology (H&E). Fluorescence intensities were measured from sets of 3 (dashed white) 
boxes with dimensions of 20×20 µm2, Figure 3.26(A), and quantified in Figure 3.27. 
We found increased cell surface staining of ALL*-Cy5.5 compared with QLE*-Cy5.5 to Hep3B 
xenograft (arrows), Figure 3.26(A-B). Overexpression of GPC3 on cell surface of Hep3B 
xenograft was confirmed with GPC3 antibody, Figure 3.26(C). No staining was observed for 
either peptide with SK-Hep1 xenograft, Figure 3.26(D-E), which had no GPC3 expression, 
Figure 3.26(F). Minimal staining was observed with ALL*-Cy5.5 on normal mouse liver tissue, 
Figure 3.26(G), but no staining was observed with QLE*-Cy5.5, Figure 3.26(H). The same 
staining level was observed with GPC3 antibody, Figure 3.26(I).  
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Figure 3.26 Validation of specific peptide binding to GPC3 overexpressed by mouse HCC xenograft tumors. On confocal 
microscopy, we found intense staining of (A) ALL*-Cy5.5 compared to (B) QLE*-Cy5.5 to sections of Hep3B xenograft tumors. 
Fluorescence intensities were measured from sets of 3 (dashed white) boxes with dimensions of 20×20 µm2. (C) With a known 
GPC3 antibody, we confirmed overexpression of GPC3 on cell surface of Hep3B xenograft (arrows) (D-E) No staining of ALL*-
Cy5.5 and QLE*-Cy5.5 was observed to sections of SK-Hep1 xenograft tumors. (F) With a known antibody, we confirmed 
negative expression of GPC3 in SK-Hep1 xenograft (G-H) Minimal staining was observed with either ALL*-Cy5.5 or QLE*-
Cy5.5 to normal liver (I) low GPC3 expression was observed with anti-GPC3 antibody staining. 
Greater intensity from peptide binding to HCC than normal was found with 2.22-fold difference, 
P = 8.0×10-15 by two-sample t-test, n=26, Figure 3.27(A). The corresponding ROC curve showed 
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96.2% sensitivity and 92.3% specificity for distinguishing HCC from normal liver with an area 
under curve of AUC = 0.98, Figure 3.27(B). 
 
Figure 3.27 Quantification of IF on mouse tissue. (A) Greater intensity from peptide binding to HCC than normal was found with 
2.22-fold difference, P = 8.0×10-15 by two-sample t-test, n=26. (B) The corresponding ROC curve showed 96.2% sensitivity and 
92.3% specificity for distinguishing HCC from normal liver with an area under curve of AUC = 0.98. 
Histology (H&E) showed features of enlarged nuclei (arrow) and highly invasive vasculature 
(arrowhead) in Hep3B xenograft tumor sections, Figure 3.28(A). A nest of SK-Hep1 tumor cells 
with large irregular round nuclei (arrow) and infiltrating blood vessels lined with flattened 
endothelial cells (arrowhead) can be seen, Figure 3.28(B). Corresponding histology (H&E) for 
normal liver showed lobule with central vein (arrowhead) surrounded by radially aligned plates 
of hepatocytes, Figure 3.28(C).  
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Figure 3.28 H&E histology of HCC xenograft and normal liver. (A) Histology (H&E) of Hep3B xenograft shows features of 
enlarged nuclei (arrow) and highly invasive vasculature (arrowhead). (B) A nest of SK-Hep1 tumor cells with large irregular 
round nuclei (arrow) and infiltrating blood vessels lined with flattened endothelial cells (arrowhead) can be seen. (C) Histology 
of normal mouse liver shows lobule with central vein (arrowhead) surrounded by radially aligned plates of hepatocytes. 
Co-localization of binding by peptide (red) and antibody (green) occurred in dysplasia, Pearson’s 
correlation coefficient ρ = 0.57, Figure 3.29(A). However, scrambled peptide QLE*-Cy5.5 
stained minimally and non-specifically on Hep3B xenograft, which did not co-localize with that 
of the antibody, Pearson’s correlation coefficient ρ = 0.10, Figure 3.29(B).  
 
Figure 3.29 Co-localization of targeting and control peptide. (A) Binding of ALL*-Cy5.5 and anti-GPC3-AF488 colocalized to 
surface of cells in xenograft HCC tissue, Pearson’s coefficient ρ = 0.57±0.08. (B) Binding of QLE*-Cy5.5 and anti-GPC3-AF488 
did not colocalize to surface of cells in xenograft HCC tissue, Pearson’s coefficient ρ = 0.10±0.04. 
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3.6 In vivo validation of GPC3 peptide targetability 
The in vitro and ex vivo validations in Section 3.4 and 3.5 of ALL*-Cy5.5 probe binding to 
GPC3 in both HCC cell lines and resected mouse xenograft respectively have provided valuable 
evidence of ALL *-Cy5.5 probe’s ability to detect cell surface GPC3 overexpression in HCC. 
Rather than being applied directly onto cultured cells or tumor sections, in vivo animal tumor 
model validation challenges the delivery of peptide to tumor site after injecting the probe into the 
blood stream of the mouse. Therefore, the probe’s performance in in vivo imaging of HCC 
mouse model would inform the potential of clinical translation value of the probe in HCC 
patients. 
3.6.1 In vivo whole body fluorescent imaging 
Near NIR labeled GPC3-targeting peptide 250μL 300μM ALL*-Cy5.5 were injected via tail vein 
in mice bearing subcutaneous HCC xenograft tumors and tracked over time before and after 
injection with the IVIS Spectrum in vivo imaging system (PerkinElmer, MA). At 0.5, 1, 2, 4, and 
24 hours following tail vein injections, mice were imaged (ventral and dorsal presentations) with 
a 675nm excitation wavelength, 710nm emission filter and a 0.05 second exposure time. 
Fluorescence signal was measured as average radiance (p/sec/cm2/sr) in tumor area with Living 
Image software (v4.5.2, Caliper Life Sciences, MA). Same amount of scrambled control peptide, 
QLE*-Cy5.5 and free dye Cy5.5 were injected and imaged under the same conditions. Target-to-
background ratios were calculated by dividing signal from the tumor with that from non-tumor 
bearing flank in ROIs of equal area on each mouse. Mice were fed alfalfa-free diet (TD.97184, 
Harlan Teklad, WI) to prevent auto fluorescence from chlorophyll in food. 
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Figure 3.30 Time course of whole body fluorescence imaging in mice injected with peptide. Representative whole-body images 
show peak uptake in GPC3 positive tumor (from Hep3B cells, arrowheads) at 2 hours after i.v. injection of A) ALL*-Cy5.5. 
Results are also shown for B) scrambled peptide QLE*-Cy5.5 and C) unlabeled Cy5.5 dye alone over the time course of 0.5 ~ 24 
hours. (D) Whole-body time course images was taken 2 hrs after ALL*-Cy5.5 was injected in mice bearing GPC3 negative tumor 
(from SK Hep-1 cells, arrows). 
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Mice bearing HCC xenograft tumor (arrowheads) were i.v. injected GPC3 targeting peptide 
ALL*-Cy5.5, scrambled control peptide QLE*-Cy5.5 and unlabeled Cy5.5 free dye alone. 
ALL*-Cy5.5 was also injected in mice bearing GPC3 negative tumor (from SK Hep-1 cells, 
arrows) as control of EPR effect. Pre-injection imaging confirmed no autofluorescence was 
present. NIR images were taken over the time course of 0.5 ~ 24 hours post injection, Figure 
3.30(A-D).  
 
Figure 3.31 Quantification of in vivo whole body fluorescence imaging. (A) Quantitative analysis of log-transformed data showed 
the mean signal from ALL*-Cy5.5 to be significantly higher than that of scrambled control peptide and free dye alone at 2 hours 
post injection (P = 1.4×10-8 and 1.7×10-12 respectively). Signal from Cy5.5 dye alone peaked at 0.5 hour post injection and was 
significantly higher than either peptide (P = 3.7×10-6 and 1.5×10-5 respectively). Signal from ALL*-Cy5.5 on GPC3 negative 
tumors served as negative control for EPR effect. (B) Mean±SD target-to-background (T/B) ratio of ALL*-Cy5.5 at 2 hours was 
3.91±0.58 versus 1.12±0.19 for QLE*-Cy5.5, P = 1.1×10-12. 
Quantitative analysis of log-transformed data shows the mean signal from ALL*-Cy5.5 to be 
significantly higher than that of scrambled control peptide and free dye alone at 2 hours post 
injection (P = 1.4×10-8 and 1.7×10-12 respectively). Signal from Cy5.5 dye alone was non-
specific to tumor site, which peaked at 0.5 hour post injection and was significantly higher than 
either peptide (P = 3.7×10-6 and 1.5×10-5 respectively). Figure 3.31(A). Mean±SD target-to-
background (T/B) ratio of ALL*-Cy5.5 at 2 hours was 3.91±0.58 vs 1.12±0.19 for QLE*-Cy5.5, 
P = 1.1×10-12., Figure 3.31(B). 
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3.6.2 Biodistribution of peptide in organs 
To assess the biodistribution of peptide probe, mice (n = 5) were sacrificed 2 hours after 
injection of 250μL 300μM ALL*-Cy5.5. The organs were harvested and imaged ex vivo. Mice 
injected with scrambled control peptide QLE*-Cy5.5 and free dye Cy5.5 were imaged with the 
same filters and exposure time as Section 3.6.1. ALL*-Cy5.5 was also injected in GPC3 negative 
tumor bearing mice as EPR control. Absence of auto fluorescence was confirmed in PBS 
injected mice. The amount of fluorescent signal in each organ was quantified as a percentage of 
total fluorescence signal (p/s) in each mouse. 
 
Figure 3.32 Fluorescent imaging of peptide in major organs after systemic injection. Representative fluorescence images of 
excised organs 2 hours following intravenous injection of ALL*-Cy5.5, scrambled peptide QLE*-Cy5.5, Cy5.5 dye alone, and 
PBS on GPC3 positive tumor bearing mice. In addition, ALL*-Cy5.5 was also injected in GPC3 negative tumor bearing mice as 
control. 
To investigate tissue uptake of peptide in mice, ex vivo fluorescence images were taken of 
internal organs as well as resected tumor at 2 hours post injection of probes, Figure 3.32. Free 
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Cy5.5 dye and Cy5.5 labeled targeting and scrambled peptides accumulated most in the liver and 
kidneys of mice, followed by GI tract and spleen. Much higher targeting peptide accumulation 
was observed in tumor than all other groups. Probe distribution inside liver could potentially 
mask signals from tumor in clinical setting of image guided surgery. This concern was best 
addressed with orthotopic xenograft model described in Section 5.1.3. Minimal accumulation 
was observed in brain, heart and stomach. No fluorescent signal was observed in negative control 
group injected with same volume of PBS. 
 
Figure 3.33 Biodistribution of peptide in mouse organs after systemic injection. Quantification of fluorescent signals in each 
organ. Signal in the tumor was significantly higher in ALL*-Cy5.5 injected mice than the scrambled control probe, Cy5.5 dye 
alone, or on GPC3 negative tumor (P = 6.5×10-4, 2.3×10-4 and 2.2×10-3 respectively, n = 5), by ANOVAs for each tissue. 
Quantification of fluorescent signals in each organ showed signal in the tumor was significantly 
higher in ALL*-Cy5.5 injected mice than the scrambled control probe, Cy5.5 dye alone, or on 
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GPC3 negative tumor (P = 6.5×10-4 and 2.3×10-4 and 2.2×10-3 respectively, n = 5), by ANOVAs 
for each tissue. Figure 3.33. 
3.6.3 In vivo laparoscopic fluorescence image 
In vivo laparoscopic fluorescence image were collected with the same instrument described in 
Section 2.3. Nude mice with human HCC xenograft 2 weeks post implantation were tail vein 
injected with 200μL 300μM GPC3 peptide ALL*-Cy5.5. Laparoscopic images were taken 2 
hours post injection in both fluorescence and reflection mode simultaneously. Following imaging, 
resected xenografts were fixed and formalin embedded for immunohistochemistry and 
immunofluorescence staining as described previously. 
 
Figure 3.34 In vivo fluorescence laparoscopic imaging of HCC xenograft. Representative (A) Fluorescence and (B) reflectance 
images of mouse injected with ALL*-Cy5.5 were collected with the NIR laparoscope 2 hours after intravenous injection of 
ALL*-Cy5.5. (C) Representative white light images. Representative (D) Fluorescence, (E) reflectance and (F) white light images 
of mouse injected with QLE*-Cy5.5 in a different mouse.  
Fluorescence and reflectance images, Figure 3.34(A-B), were collected with the NIR laparoscope 
2 hours after intravenous injection of the GPC3-targeting peptide, ALL*-Cy5.5, in Hep3B 
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xenograft bearing mice. The same set of images were collected with scrambled peptide QLE*-
Cy5.5 in a different tumor bearing mouse, Figure 3.34(D-E). White light images were collected 
for mouse injected with targeting peptide ALL*-Cy5.5, Figure 3.34(C), and scrambled peptide 
QLE*-Cy5.5, Figure 3.34(F). 
Automatic ROI identification from heat map digital images was performed as described in 
Section 2.3.5. Heat map digital image that rectifies imaging distance was generated by taking the 
ratio between corresponding fluorescence and reflectance images pixel by pixel, Figure 3.35(A). 
Region of interest (ROI) was segmented by automatic imaging processing from ratio image 
following Otsu’s method, Figure 3.35(B). The same set of images were analyzed for scrambled 
peptide QLE*-Cy5.5 in a different tumor bearing mouse, Figure 3.35(C-D). 
 
Figure 3.35 Segmentation of ROIs from heat map images. (A) Heat map corrects for imaging distance by taking the ratio between 
co-registered fluorescence and reflectance images. (B) Region of interest was segmented by imaging processing algorithm using 
ratio image. (C-D) The same set of images were generated with scrambled peptide QLE*-Cy5.5 in a different tumor. 
ROI in images of targeted peptide resulted in an average target-to-background ratio of ALL*-
Cy5.5 (6.2±0.9) significantly higher (P=3.5×10-7 on log-transformed data, 2.9-fold larger) than 
that of QLE*-Cy5.5 (2.1±0.5), by two-sample t-test with n = 8 mice in each group, Figure 3.36.  
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Figure 3.36 Target-to-background ratios of segmented laparoscopic images. Target-to-background ratio of ALL*-Cy5.5 (6.2±0.9) 
is significantly higher (P=3.5×10-7 on log-transformed data, 2.9-fold larger) than that of QLE*-Cy5.5 (2.1±0.5), by two-sample t-
test with n = 8 mice in each group. 
On immunohistochemistry, anti-GPC3 antibody stained strongly on cellular membrane (arrow) 
of tumor cells surrounding infiltrating blood vessel (arrow head) in resected HCC tumor 
xenograft, Figure 3.37(A). On confocal fluorescence microscopy, intense staining of ALL*-
Cy5.5 to surface of Hep3B human HCC cells (arrowheads) on excised tumor xenograft were 
shown at 40X magnification, Figure 3.37(B). 
 
Figure 3.37 IHC and IF for GPC3 expression in HCC xenograft. (A) Immunohistochemistry (IHC) with anti-GPC3 antibody 
showed increased reactivity to HCC. A nest of tumor cells with large irregular round nuclei (arrows) and infiltrating blood 
vessels lined with flattened endothelial cells (arrowhead) can be seen. (B) Immunofluorescence image of fresh resected HCC 
tumor xenograft 2 hours after ALL*-Cy5.5 injection. 
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3.6.4 In vivo hand held dual-axis confocal microscopic imaging 
A custom made hand held dual-axis confocal microscopic system was used to visualize peptide 
binding to HCC xenograft tumor with cellular resolution in vivo. Meanwhile, this instrument is 
capable of collecting both horizontal and vertical cross section of tissue image in vivo, and thus 
can validate the probe penetration into tumor with systemic delivery [138].  
 
Figure 3.38 Hand-held dual-axis confocal microscope for in vivo imaging. (A) Handheld dual axes confocal endomicroscope was 
used to collect real-time in vivo images with sub-cellular resolution. (B) The distal tip of instrument was placed in contact (inset) 
with the lesion in live tumor-bearing mouse. Strong uptake (arrow) of ALL*-Cy5.5 is seen in tumor on optical sections collected 
in the 
The probe was small enough to be comfortably held in the surgeon’s hand during surgery, Figure 
3.38(A), for in vivo imaging of biomarker expression. Its diameter was 5.5 mm and delivered 
671nm near-infrared laser at 2 mW. Mouse carrying HCC xenograft tumor overexpressing GPC3 
was first injected with 250μL 300μM ALL*-Cy5.5 peptide intravenously and after 2 hours the 
probe was held in contact with exposed subcutaneous tumor to acquire in vivo peptide binding 
images, Figure 3.38 (B). Images were collected in either the vertical or horizontal plane with 430 
μm depth or 1000×1000 µm2 area, respectively, at 5 frames per second. With measured lateral 
resolution of 2.49 μm and axial resolution of 4.98 μm, each peptide stained cell can be clearly 
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seen (arrows). A reconstructed 3D MIP image reveals all the stained cells in the tumor.
 
Figure 3.39 In vivo dual-axis confocal imaging of HCC xenograft. Strong uptake (arrow) of ALL*-Cy5.5 is seen in tumor on 
optical sections collected in the (A) horizontal (1000×1000 µm2) and (B) vertical (1000×430 µm2) planes, respectively. (C) A 
series of vertical cross-section images were reconstructed into 3D MIP volume. (D) Minimal staining was observed in xenograft 
tumor from control peptide QLE*-Cy5.5. (F) 2.9-fold increase (47±13 vs 16±4, P = 2.2×10-6) in fluorescent intensity was 
observed in ALL*-Cy5.5 injected mice at tumor compared to control peptide QLE*-Cy5.5. 
Figure 3.39 captured strong uptake (arrows) of ALL*-Cy5.5 in tumor on optical sections 
collected in the horizontal (1000×1000 µm2, Video 3.1) Figure 3.39(A) and vertical (1000×430 
µm2, Video 3.2) Figure 3.39(B) planes, respectively. A series of vertical cross-section images 
were reconstructed into 3D MIP volume (Video 3.3), Figure 3.39(C). Minimal staining was 
observed in xenograft tumor from control peptide QLE*-Cy5.5 in the horizontal and vertical 
planes, Figure 3.39(D-E). Fluorescent signal of ALL*-Cy5.5 is significantly higher (P=2.2×10-6 
on log-transformed data, 2.9-fold larger) than that of QLE*-Cy5.5, by two-sample t-test with n = 
8 mice in each group, Figure 3.39(F).  
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Video 3.1 Horizontal plane in vivo confocal recording 
 
Video 3.2 Vertical plane in vivo confocal recording 
 
Video 3.3 3D in vivo image of ALL*-Cy5.5 in HCC 
3.6.5 Toxicity 
 
Figure 3.40 Histology of vital organs post peptide administration. Mice bearing human HCC xenograft tumors were sacrificed 2 
hours post-injection of ALL*-Cy5.5. No signs of acute peptide toxicity were seen in A) brain, B) heart, C) lung, D) liver, E) 
spleen, F) kidney, G) stomach, H) intestine, I) cecum, J) colon. 
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Vital organs were harvested post peptide administration in mice to evaluate acute toxicity of 
peptide probe with histology observation. Mice bearing human HCC xenograft tumors were 
sacrificed 2 hours post-injection of ALL*-Cy5.5. No signs of acute peptide toxicity were seen in 
brain, heart, lung, liver, spleen, kidney, stomach, intestine, cecum, colon, Figure 3.40(A-J). 
3.7 Human tissue validation 
Up till now, all the experiments were conducted with human cell lines with known GPC3 
expression levels. How well GPC3 targeting peptide perform on diverse human tissues with 
unknown GPC3 expression levels would shed light on the clinical translation potential of this 
probe. To this end, patient biopsy samples were collected from U.S. and China respectively, and 
immunofluorescent staining was performed on different tissue types. 
3.7.1 Microscopic validation on U.S. patent liver biopsies 
Specific peptide binding to human HCC was confirmed on patient biopsies (n=41) ex vivo from 
University of Michigan Hospital. On immunofluorescence, ALL*-Cy5.5 showed negative 
staining (red) to human normal liver tissue from specimens, Figure 3.41(A). Antibody staining 
(green) of the same tissue confirmed minimal GPC3 expression, Figure 3.41(B). Binding by 
ALL*-Cy5.5 peptide (red) and AF488-labeled anti-GPC3 antibody (green) co-localizes on 
normal liver specimen with Pearson’s correlation coefficient of ρ = 0.62, Figure 3.41(C). Co-
stained regions were also imaged at 40X, Figure 3.41(D) and 100X (red dashed box in Panel D), 
Figure 3.41(E) magnifications. Minimal staining was observed in adenoma tissue with Pearson’s 
correlation coefficient of ρ = 0.63, Figure 3.41(F-J), and moderate diffuse staining was observed 
in cirrhotic liver tissue with Pearson’s correlation coefficient of ρ = 0.57, Figure 3.41(K-O). 
Strong intense staining with Pearson’s correlation coefficient of ρ = 0.66 was observed in HCC 
tissue, Figure 3.41(P-S). Cell surface staining (arrow) is shown in Figure 3.41(T). 
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Figure 3.41 Specific peptide binding to human HCC ex vivo. (A) On immunofluorescence (IF), ALL*-Cy5.5 showed negative 
staining (red) to human normal liver tissue from specimens. (B) Antibody staining (green) of the same tissue confirmed minimal 
GPC3 expression. (C) Binding by ALL*-Cy5.5 peptide (red) and AF488-labeled anti-GPC3 antibody (green) co-localizes on 
normal liver specimen with Pearson’s correlation coefficient of ρ = 0.62. Co-stained regions were also imaged at (D) 40X and (E) 
100X (red dashed box in Panel D) magnifications. (F-J) Minimal staining was observed in adenoma tissue with Pearson’s 
correlation coefficient of ρ = 0.63 and (K-O) moderate diffuse staining was observed in cirrhotic liver tissue with Pearson’s 
correlation coefficient of ρ = 0.57. (P-S) Strong intense staining with Pearson’s correlation coefficient of ρ = 0.66 was observed 
in HCC tissue (T) showing cell surface staining (arrow). 
Figure 3.42(A) summarized quantitative comparison of ALL*-Cy5.5 binding to human HCC 
with normal liver, adenoma and cirrhosis tissue. We fit an ANOVA model with terms for 4 
conditions and 41 patients (n=7 for normal and adenoma, n= 12 for cirrhosis and n=15 for HCC) 
to log-transformed data and found a 3.43-fold greater (P=8.6×10-10) signal for ALL*-Cy5.5 in 
HCC than normal, and 2.48-fold increase (P=2.7×10-6) from adenoma and 2.05-fold increase 
(P=2.7×10-6) from cirrhosis. The corresponding ROC curve showed 93% sensitivity at 88% 
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specificity for distinguishing HCC from all non-HCC tissue with an area under curve of AUC = 
0.98, Figure 3.42(B). ROC curve shows 87% sensitivity at 100% specificity for distinguishing 
HCC from cirrhosis with an area under curve of AUC = 0.97, Figure 3.42(C).
 
Figure 3.42 Quantification of peptide staining on human biopsies. (A) Quantitative comparison of ALL*-Cy5.5 binding to human 
HCC with normal liver, adenoma and cirrhosis tissue. We fit an ANOVA model with terms for 4 conditions and 41 patients (n=7 
for normal and adenoma, n= 12 for cirrhosis and n=15 for HCC) to log-transformed data and found a 3.43-fold greater 
(P=8.6×10-10) signal for ALL*-Cy5.5 in HCC than normal, and 2.48-fold increase (P=2.7×10-6) from adenoma and 2.05-fold 
increase (P=2.7×10-6) from cirrhosis. (B) The corresponding ROC curve showed 93% sensitivity at 88% specificity for 
distinguishing HCC from all non-HCC tissue with an area under curve of AUC = 0.98. (C) ROC curve shows 87% sensitivity at 
100% specificity for distinguishing HCC from cirrhosis with an area under curve of AUC = 0.97. 
Immunohistochemistry (IHC) with anti-GPC3 antibody stained negative on normal liver, 
moderately on adenoma and cirrhosis human tissue, Figure 3.43(A-C). Intense staining was 
observed in HCC human tissue, Figure 3.43(D). Figure 3.43(E-H) show corresponding 
representative histology (H&E) for normal, adenoma, cirrhosis and HCC. All 41 biopsies were 
diagnosed by pathologist and the patients’ medical history and histology notes were recorded in 
Table 3.4. 
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Figure 3.43 IHC and histology of patient biopsies. Immunohistochemistry (IHC) with anti-GPC3 antibody stains negative on (A) 
normal liver, (B) moderately on adenoma and (C) cirrhosis human tissue. (D) Intense staining was observed in HCC human 
tissue. Corresponding representative histology (H&E) for (E) normal, (F) adenoma, (G) cirrhosis and (H) HCC. 
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Table 3.4 Diagnosis and patient medical history of human tissue samples 
3.7.2 Microscopic validation on Chinese patent liver biopsies 
Many HCC cases in Asian countries such as China are HBV related while it’s much less 
common in North America where HCV background is more prevalent. To further validate the 
targeting of peptide, preliminary experiment was conducted on patient HCC biopsies from 
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Peking University People’s Hospital, Figure 3.44. On confocal microscopy, we found intense 
staining of ALL*-Cy5.5 (red) to sections of human hepatocellular carcinoma Figure 3.44(A). 
Increased fluorescence intensity was observed for staining of anti-GPC3-AF488 antibody (green) 
to human hepatocellular carcinoma, Figure 3.44 (B). On immunohistochemistry with a known 
GPC3 antibody, we confirmed overexpression of GPC3 in human HCC, Figure 3.44 C). 
 
Figure 3.44 ALL* peptide validation on Human HCC. (A) On confocal microscopy, we found Intense staining of ALL*-Cy5.5 
(red) to sections of human hepatocellular carcinoma. (B) Increased fluorescence intensity was observed for staining of anti-
GPC3-AF488 antibody (green) to human hepatocellular carcinoma. (C) On immunohistochemistry with a known GPC3 antibody, 
we confirmed overexpression of GPC3 in human HCC. 
3.8 Discussions 
Compared to previous attempts to identify HCC targeting peptide, ALL*-Cy5.5 probe showed 
superiority in terms of clear target molecule identity, higher affinity and clinically favorable 
pharmacokinetic profile. Lo et al have previously identified 12-mer peptide, SP94, that 
specifically binds to HCC cells such as HepG2 and Huh-7, but not to hepacocytes [182]. 
Subsequent studies have conjugated the peptide to nanocarriers, bacteriophage MS2 virus-like 
particles, and radiopharmaceutical labels as cell specific drug delivery and imaging probes [183-
186]. However, the bio-panning was performed with human HCC cell line and thus the target 
was unknown. Recently, one study used human recombinant GPC3 protein in phage display 
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screening to identify a 12-mer GPC3 targeting peptide sequence, TJ12P1 (sequence: 
DHLASLWWGTEL), and measured its dissociation constant to be kd=280.4 ± 33.51 nM [187]. 
In their in vivo study using Cy5.5 labeled peptide, homing of peptide to HepG2 xenograft tumor 
took 4 hours. In the current study, the dissociation constant of ALL*-Cy5.5 peptide was 
kd=71.28 nM (inversely correlated to affinity) with shorter in vivo imaging peak time of 2 hours 
post injection. The reduced probe delivery time can be more manageable in clinical translational 
applications. The nearly four-fold improvement in affinity from the previous work could be 
attributed to the addition of amino acid linker sequence, GGGSK, between targeting peptide 
sequence and the near-infrared dye Cy5.5, reducing steric hindrance from the dye moiety upon 
target binding. As mentioned by the authors of TJ12P1 peptide, liver uptake of the peptide could 
be caused by the hydrophobicity of the probe, which in turn, could affect its distribution time to 
the tumor. TJ12P1-Cy5.5 probe has 0 overall charge, 7 (out of 12, 58%) hydrophobic amino 
acids and 2 polar uncharged amino acids while ALL*-Cy5.5 probe has 1 positive overall charge 
(including linker sequence), 9 (out of 17, 53%) hydrophobic amino acids and 4 polar uncharged 
amino acids. The increased charge and polarity of the probe could have helped hydrogen bond 
forming to improve solubility and distribution time of the probe. 
There are various ways to control for EPR effect when a targeted delivery to tumor with leaky 
vasculature is studied [300, 301]. For instance, targeted nanoparticles can be used as sensors to 
detect molecular interactions [301-303]. In one study, EGFR-targeted gold nanospheres 
aggregated in endosomes after undergoing receptor-mediated endocytosis [304]. This resulted in 
plasmon coupling and a red shift in the absorption spectrum, which is detectable with 
photoacoustic imaging. Therefore, nanoparticles in the endosomes of cells overexpressing EGFR 
can be detected and distinguished from free nanoparticles in the tumor, which may have 
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accumulated via the EPR effect [79]. In this study, probe accumulations from EPR effect were 
accounted for with scrambled control peptide, free NIR dye alone and target absent tumor and 
probe accumulation due to EPR was found to be insignificant and nonspecific. 
Since one marker may not be sufficient to detect all HCC cases, adoption of a panel of HCC 
markers may be a good choice. The most common combination of HCC markers is GPC3, 
HSP70 and glutamine synthetase (GS) [305-307]. Using a 3-marker panel with a minimum of 
two positives, (regardless of which), the sensitivity and specificity for the detection of eHCC-G1 
were respectively 72% and 100% [308, 309]. The most sensitive combination was 
HSP70+/GPC3+ (59%) when a 2-marker panel was used [308, 310, 311]. However, combination 
of more biomarkers may increase false negatives as well. In contrast, the combination of three 
positive markers revealed a negative detection of 100% large regenerative (LRN) and low grade 
dysplastic (LGDN), 73% high grade dysplastic (HGDN) and 3% early HCC grade 1 (eHCC-G1) 
[308]. 
3.9 Summary 
A peptide with strong binding affinity against GPC3 was identified and validated both in vitro 
and ex vivo. Our study has furnished a reliable peptide-based imaging probe, ALL*-Cy5.5, 
which can be used to monitor GPC3, with high specificity and resolution via in vivo optical 
imaging technologies. We found peak uptake at 2 hours post injection and clearance by ~24 
hours. Specific peptide bind to individual HCC cells was visualized in vivo on xenograft bearing 
mice. The peptide probe demonstrated superior diagnostic performance on diverse liver tissue 
samples from North America and China, with 93% sensitivity at 88% specificity for 
distinguishing HCC from all non-HCC tissue. This time frame is significantly faster than most 
antibodies and applicable in clinical settings. We successfully visualized a large fraction of the 
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volume of HCC tumors, and may be able to improve imaging contrast and depth with use of 
optimal contrast agents, such as nanoparticles [239]. This topic will be explored in Chapter 4. 
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Chapter 4 Targeted in vivo photoacoustic imaging with gold nanoshell 
4.1 Motivation 
To further improve the contrast and depth of tumor imaging, contrast agents tailored for 
optimized photoacoustic imaging are critically needed. With surface plasmon resonance (SPR) 
absorption of light at longer wavelength and higher extinction efficiency than organic 
fluorophores such as Cy5.5, metallic nanoparticles have been widely incorporated in targeted 
photoacoustic imaging (PAI) [114, 312-314]. Previously, gold nanospheres [79], gold nanrods 
[315], silica-coated gold nanorods [316], and silver nanoplates [317] have been labeled with 
monoclonal EGFR antibodies to image cells overexpressing EGFR [318] with photoacoustic 
imaging. By strategically conjugating ALL* to the surface of GNS, we can create a novel 
diagnostic platform for PAI to detect satellite tumor beneath HCC resection margin with high 
contrast in future clinical applications. 
4.1.1 Gold nanoshell for PAI 
As a new type of gold nanostructures, gold nanoshells (GNSs) have significant advantages in 
optical and photoacoustic imaging because they are high in absorption-to-scattering ratio, 
plasmon-tunable in the near-infrared (NIR) spectral range and easily surface functionalized [319-
321]. Gold nanoshells are concentric sphere nanoparticles consisting of a dielectric silica core 
and a gold shell [322, 323] which serves as the absorber of near-infrared (NIR) laser energy, 
Figure 4.1. By changing the size, geometry and internal structure of the GNSs, the relative 
magnitude of light being absorbed and scattered can be tuned to maximize energy absorption 
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[323]. By varying core-to-shell dimension ratio [324, 325], the plasmon-derived optical 
resonance of gold can be dramatically shifted in wavelength from the visible to the near and mid-
infrared over a wavelength range that spans the region of highest physiological transmissivity 
[323, 326]. These shells are also easily conjugated to antibodies and other biomolecules [327-
329]. Several potential biomedical applications are under development, including immunoassays, 
controlled drug delivery, photothermal cancer therapy, and imaging contrast agents [326, 328-
334]. 
 
Figure 4.1 Schematic of nanoshell probe design. Targeted gold nanoshell recognizes GPC3 on plasma membrane and serves as 
photoacoustic imaging contrast agent upon NIR laser excitation in HCC. 
Optical absorbing-dominant GNSs in the near-infrared region are valuable for PA imaging [312, 
335]. Light extinction, derived from scattering and absorption, is not only dependent on the total 
particle radius, but also on the inner dielectric core dimensions [323, 336, 337]. Extinction 
coefficient depends linearly on the total size but it is independent of the core/shell ratio [215, 338, 
339]. The absorption contribution to extinction decreases as the overall diameter increases [323]. 
The absorption cross-section of GNS is more than five orders of magnitude larger than those of 
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conventional organic dyes, such as IRDye-800 and indocyanine green (ICG) [114, 340]. GNS-
based PA imaging can enable the enhanced photoacoustic imaging (PAI) of the tumor, as well as 
delivery of photothermal therapy (PTT). In previous study, GNS was demonstrated to be 
biocompatible and can generate heat efficiently upon NIR laser irradiation [319]. However their 
potential as specific nanosensors for targeted in vivo PAI of HCC has not been studied yet. In 
this study, the use of GNS with surface coated 12-mer peptide ALL* as targeted in vivo 
photoacoustic imaging contrast agent for HCC detection was investigated. 
4.1.2 Stability and bioavailability 
The use of gold nanoparticles (GNPs) requires an appropriate colloidal stability [341, 342]. 
During the past decade colloidal GNPs have become attractive materials due to an increasing 
interest in their potential applications in biotechnology, molecular diagnostics and biomedicine 
[343-348]. Because of their unique properties such as size and shape-dependent optical and 
electronic features, good biocompatibility and the ability to bind ligands containing thiols, 
phosphines and amines, they have emerged as useful tools for the design of biosensors [344], the 
development of methods for cancer detection [349, 350] and potential vehicles for drug delivery 
[351]. The immobilization of organic molecules or biomolecules onto GNPs surface significantly 
promotes their dispersion in aqueous solutions and improves the stability of the colloidal 
suspensions [352]. Lipoic acid (LA) has been extensively used for the functionalization of gold 
surfaces [353]. In most cases, LA has been conjugated with polyethyleneglycol (PEG) units 
giving decorated LA-appended-polyethyleneglycol functionalized gold nanoparticles, thereby 
showing better stabilities than their acyclic disulfide and single thiol counterparts [353-356].  
Systemic delivery of nanoparticles also faces the challenge of overcoming immune response 
[357-359]. Most nanomaterials, when administered into the blood, are taken up within minutes or 
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hours by the phagocytic cells of the mononuclear phagocyte system (MPS) inside the liver and 
spleen [360-362]. The body’s reticuloendothelial system sweeps foreign nanoparticles (NPs) out 
of the circulation before reaching the intended target [363, 364]. By preventing opsonization, the 
addition of polyethylene glycol (PEG) drastically increases the blood half-life of all 
nanomaterials [365, 366]. The synthesis of these long-circulating “stealth” nanoparticles 
improves accumulation in the target tissue [367]. PEGylated particles were shown to have 
decreased protein binding, increased blood circulation time, and decreased cytotoxicity [368]. 
GNSs used in this study were coated with PEG to improve the solubility and bioavailability of 
the nanoprobe. 
4.1.3 Regulatory and clinical implications 
Targeted nanoshell points in the future direction of clinical application and approval [369-371]. 
With the rapidly growing interest in nanoparticle research, the toxicity of nanoparticles is 
becoming an increasingly important issue in nanotechnology [372-374]. Based on an Web of 
Science search produced by Institute for Scientific Information (ISI), the number of publications 
concerning nanoparticle toxicity has grown exponentially over the years, with 2735 papers being 
published on the subject since 2000 [375]. Nevertheless, many nanoparticle systems have been 
approved by either the FDA (U.S.) or EMA (Europe) and are used in the clinic to either treat or 
diagnose disease [376]. For imaging applications, nanoparticles have been clinically approved as 
contrast agent for both MR [377, 378] and ultrasound [379, 380] imaging. Interestingly, while 
nanoparticles and targeting antibodies are both approved for clinical use, systems combining 
these two technologies are lacking in both approved products and in clinical trials [370, 381]. 
PEG-coated gold nanoshell (non-targeting) is one of the four inorganic nanoparticle therapies 
and diagnostics currently undergoing clinical trial [376]. Thus using surface functionalized 
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peptide as active targeting mechanisms to improve biodistribution of PEG-coated gold nanoshell 
has a promising outlook of pushing nanoparticle drug delivery system further and impacting 
clinical care even more in the future. 
4.2 GPC3 targeting GNS synthesis and characterization 
4.2.1 Surface functionalization 
Monomeric linear peptides ALLANHEELFQT, hereafter ALL*, and its scrambled control 
QLELTFHANLEA, hereafter QLE*, (molecular weight = 1385.54 for both peptides) were 
synthesized as described in Section 3.3.1. Deprotection of lysine side chain exposed the amine 
group for coupling with Tetrafluorophenyl (TFP). ALL* and QLE* peptides were then 
conjugated to lipoamido-dPEG12-TFP in anhydrous DMF under basic condition for 1 hour, 
Figure 4.2.  
 
Figure 4.2 ALL* peptide is conjugated to PEG in anhydrous DMF under basic condition for 1 hour. 
Nanoshell (Nanospectra Biosciences, Inc, TX) were surface coated with GPC3 targeting peptide 
ALL* and scrambled control peptide QLE* through a lipoamido-dPEG12-TFP ester linker 
(Quanta BioDesign, Ltd., OH) using lipoic acid (LA) as an anchoring ligand [356] to improve 
biocompatibility and systemic circulation [382, 383], Figure 4.3.  
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Figure 4.3 Schematic of how PEG binds to metal surface using lipoic acid (LA) as an anchoring ligand. 
Five milliliters of the aqueous solution of ALL*-PEG-LA and QLE*-PEG-LA (100 mg/ml) were 
added to 5 ml of GNSs suspended in water (9.0×1010 GNSs/ml) respectively, and the mixture 
was stirred overnight at room temperature. To remove the unreacted PEG precursor from the 
solution, GNSs were centrifuged at 13,000 rpm for 10 min, the supernatant was decanted, and 
the particles were resuspended in PBS; this was done three times. Peptide-PEG-coated GNSs 
were suspended in 5 ml of PBS and stored at 4 ⁰C. Physical size and morphology of the GNS 
were characterized with transmission electron microscopy (TEM) (JOEL JEM-1400) and Cs-
Corrected HAADF (high angle annular dark field) scanning transmission electron 
microscopy (STEM) (JEOL 2100F). Hydrodynamic size and surface charge of the GNS 
conjugates were evaluated using dynamic light scattering (DLS) spectroscopy. The size and 
charge analysis of GNS (carbonate ion coated), GNS-PEG, GNS-ALL and GNS-QLE was 
carried out using Zetasizer Nano series (ZSP) from Malvern with Zetasizer software 6.0 as the 
interface. 
GNS was prepared in a K2CO3 solution. Lipoamido-dPEG12-TFP ester was attached to GNSs by 
mixing PEG-LA with aqueous solution of GNSs overnight at room temperature using lipoic acid 
(LA) as an anchoring ligand. Polyethylene glycol (PEG)-coated gold nanoshells were then 
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conjugated with targeting, Figure 4.4(A), and scrambled, Figure 4.4(B), peptides via a common 
peptide spacer sequence GGGSK.  
 
Figure 4.4 Schematic representation of surface functionalization of GNS. (A) 12-mer targeting peptide and (B) scrambled control 
peptide (black) were coated to the GNS surface respectively through GGGSK linker (green) and lipoamide-dPEG12 spacer (blue). 
4.2.2 Size and stability 
Figure 4.5 shows the TEM image of GNS for size measurement and confirmation of the 
spherical gold shell morphology. 15-17nm thick Au shell (black) coated the silica core (grey).  
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Figure 4.5 TEM image of GNSs. TEM image of GNSs displayed spherical particles with average size of 136.3 ±7.7nm (n > 150). 
15-17nm thick gold shell (black) coated the silica core (grey). Inset image showed one GNS particle in high angle annular dark 
field (HAADF) scanning transmission electron microscopy (STEM) 
The average diameter of GNS was 136.3 ±7.7nm (n > 150, polydispersity index = 0.19), which 
was consistent with the measurement by dynamic light scattering (DLS) in Table 4.1. The bare 
GNS had net negative potential (−27.1±3.8 mV) due to the presence of carbonate ions on the 
surface. Introducing a layer of lipoamido-dPEG12-TFP ester to the GNSs masked the negative 
charge and resulted in almost neutral GNS-PEGs (3.1±2.4 mV) due to the replacement of 
carbonate ions by PEG. After conjugation with ALL and QLE peptides, the charge value was 
reversed to negative (−25.1±4.3 mV and −20.6±3.1 mV), due to the large amount of negatively 
charged peptide units conjugated to PEG chains.  
 
Table 4.1 Size and zeta potential of gold nanoshells. Nanoshell sizes were measured after different surface modifications. 
Negative surface charge was observed after conjugating peptide on particle surface. 
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No precipitation was observed for ALL*-GNS s after storage at 4 °C for three months and their 
sizes remained nearly the same, Figure 4.6.  
 
Figure 4.6 Stability of GNSs over time. GNSs were kept in liquid suspension and the size stayed stable for three months. 
In addition, the physiological stability of peptide conjugated GNSs was tested in cell culture 
medium (1011/mL, Eagle's Minimum Essential Medium (EMEM) with 10% FBS). No obvious 
changes in their size and absorption were observed after incubation for 24 h. These data indicate 
good chemical and physiological stability of GNS for in vivo imaging applications.  
4.2.3 Light extinction 
The extinction coefficient of ALL*-GNS peaked at 770nm which coincided with that of the 
photoacoustic instrument laser output energy in the NIR range (680—950 nm), Figure 4.7. 
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Figure 4.7 Extinction coefficient of GNS. Extinction coefficient of ALL*-GNS over the near-infrared range (680-950nm) peaked 
at 770nm, the same wavelength as the maximal laser energy output of photoacoustic imaging instrument. 
4.3 Photoacoustic imaging of HCC xenograft tumor  
We used the photoacoustic tomography system described in Section 2.4.4 with the same set of 
imaging parameters except excitation wavelength. A transparent imaging tray located above the 
transducers was used to contain anesthetized animals, Figure 4.8(A). A dimple in the imaging 
tray was designed to place the xenograft tumor in the center of imaging field, Figure 4.8 (B-C). 
At 2 weeks post inoculation, animals (n = 8) were administered 200 μL 1×1011/mL ALL*-GNS, 
and placed inside the tray with the subcutaneous tumor positioned inside a water-filled dimple to 
couple the ultrasound signal. We acquired images with ex = 770 nm at 0, 1, 2, 4, 8, and 12 hours. 
Preliminary study was performed to determine wash out time after injecting either targeting or 
control peptide. 
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Figure 4.8 Hep3B xenograft mouse model. (C) A schematic showing the relative positions of mouse, imaging tray, light path and 
transducers during photoacoustic imaging, adapted with permission from http://www.endrainc.com. (B) Nude mouse with flank 
xenograft Hep3B tumor was placed inside a transparent imaging tray in supine position. The mouse was under anesthesia by 
inhaling 2% isoflurane delivered through nose cone (left). Flank HCC tumor (arrow) was positioned inside a dimple (dashed 
circle) at the bottom of imaging tray so that it will be at the center of field of view on photoacoustic images. White light camera 
took the image from the left side of mouse outside the imaging tray. (C) Another white light camera took the image of the mouse 
from the bottom of the imaging tray (looking along the laser light path) to make sure the HCC tumor (arrow) is placed in the 
center of the dimple (dashed circle). 
The 3D maximum intensity projection (MIP) images were reconstructed after completion of 
imaging using data acquired from all 128 transducers at each view with a back-projection 
algorithm as described in Section 2.4.5. Representative photoacoustic images were shown at a 
mean (±SD) depth of 9.7±1.4 mm 0 to 2.1 cm below the skin surface. This imaging depth was 
achieved using 2.5 mJ/cm2 laser fluence on the tissue surface, which is only 1/8 of the American 
National Standards Institute (ANSI) safety limit (20 mJ/cm2) [56, 57]. At this time, the tumors 
had reached a mean (±SD) size of 45.96±8.91 mm3 by ultrasound measurement. For ALL*-GNS 
injected group, the tumors showed increased signal in a heterogeneous pattern with visible blood 
vessels, Figure 4.9(A-F). The contrast in tumors remarkably increased in the first two hours after 
injection, indicating the gradual accumulation of ALL*-GNS in tumors. Imaging was repeated 
with QLE*- GNS, Figure 4.9(G-L). For additional control, images from HCC with and GNS-
PEG alone (PEGylated nanoshell without peptide), Figure 4.9(M-R), were shown. For QLE*-
GNS and GNS-PEG injected groups, no significant enhancement in PA images was observed 
compared with non-tumor bearing flank. Ultrasound image of tumor was taken to determine size 
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of tumor ROI in photoacoustic imaging quantification, Figure 4.9(S). White light photograph of 
tumor bearing mouse in the photoacoustic imaging tray was taken to provide anatomic 
information on the position of tumor on the mouse, Figure 4.9(T). The circle marks the FOV of 
PAI and the arrow points to the Hep3B subcutaneous xenograft. A volume rendered image of the 
tumor at 2 hours post injection was reconstructed in Figure 4.10. The 3D MIP rendering of tumor 
and surrounding vasculature from 2D PA signal was animated in Video 4.1. 
 
Figure 4.9 Photoacoustic imaging of HCC with targeted gold nanoshell. Representative MIP images at depth of 2.1 cm were 
collected at 0, 1, 2, 4, 8 and 12 hours after injection with (A-F) targeted ALL*-GNS and (G-L) scrambled control probe QLE*-
GNS are shown. In panel (A), the dashed circle defined region of interest (ROI) used to measure signal from tumor, and the same 
area in the image of normal flank (not shown) opposite to tumor implanted flank was used to measure background. (M-R) Images 
of tumor with injection of GNS alone (no peptide) were taken. The targeting probe demonstrated tumor uptake after 1 hour, 
peaked at 2 hours and cleared in 12 hours. (S) Xenograft size was measured with dashed elliptical ROI in ultrasound image of 
HCC and the longer axis was used as circular ROI diameter in PAI quantification. (T) White light image was taken of HCC 
tumor (arrow) bearing mice inside PA imaging tray in supine position. Dashed circle marked the PAI field of view. 
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Figure 4.10 3D reconstruction of targeted gold nanoshell in HCC. 3D rendering of photoacoustic signal from ALL*-GNS in HCC 
tumor at 2 hrs post injection. 
 
Video 4.1 3D PAI of nanoparticle in HCC 
4.3.1 Pharmacokinetics of GPC3 targeting GNS 
To quantify the pharmacokinetics of GPC3 targeting GNS, the average photoacoustic intensity 
from the tumor in each MIP image was measured using a circular region of interest (ROI) (white 
circles in Figure 4.9(A)) with diameter determined from US, Figure 4.9(S), and an identical ROI 
area was used in the image from the normal flank of mouse at corresponding time points to 
normalize PA signal at tumors. The normalized time curve of average PA signal was plotted in 
Figure 4.11. For QLE*-GNS and GNS-PEG injected groups, the PA enhancements peaked at 1 h 
after injection by 1.3 and 1.37- fold. Then the signal gradually returned to the original level after 
12 h. This temporal signal increase showed a small effect of tumor permeability and retention 
(EPR) [58, 59] in the leaky tumor vasculature [60]. For ALL*-GNS injected group, the PA 
enhancement was 1.72, 4.45 3.03 and 1.41-fold at 1, 2, 4, and 8 h after injection, with peak 
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enhancement at 2 h after injection. Then the signal reduced to original level after 12 h. Statistical 
significance between the groups was assessed at each time point using two-tailed Student’s t-test. 
The remarkable difference between the two groups in time-signal curves clearly demonstrated 
the tumor targeting ability of ALL*-GNS. 
 
Figure 4.11 Time course of ROI quantification of PA signal (n = 8). The targeting probe ALL*-GNS demonstrated tumor uptake 
after 1 hour, peaked at 2 hours and cleared in 12 hours. Peak contrast occurred at 2 hours post injection. Error bars represent 
standard deviation. *p < 0.05. 
4.3.2 Biodistribution of GPC3 targeting GNS 
To understand the biodistribution of ALL*-GNS in vivo, gold concentrations in various organs 
and tumors was analyzed after one-dose injection. The extraction of gold from tissues/organs 
was done as described previously [55] with certain modifications. Nude mice with Hep3B 
xenografts were i.v. injected with 200 μ L, 40 mg/mL (i.e. 2mg/g body weight, concentration = 
1011/ml) of ALL*-GNS and sacrificed at 2 h and 24 h post-injection (n = 5/group) respectively. 
The brain, liver, spleen, lungs, kidneys, heart, stomach, GI tract, and tumor were collected, 
weighed and lyophilized. The dried tissues were then completely lysed in 10 ml of aqua regia in 
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screwcap glass bottles (20ml) separately. Excess aqua regia was evaporated at room temperature. 
The residues were then redissolved in 10ml of 0.05M HCl, ultrasonicated for 20min and the 
resultant samples were analyzed by inductively coupled plasma - optical emission spectroscopy 
(ICP-OES) (Optima 2000 DV) with Winlab software (Perkin-Elmer). Biodistribution in each 
organ was quantified as percentage of injection dose (% ID). 
 
Figure 4.12 Biodistribution of targeted gold nanoshell in organs after systemic administration was measured by inductively 
coupled plasma - optical emission spectroscopy (ICP-OES) at 2 h and 24 h (2mg/g body weight) after i.v. injection of ALL*-
GNS (n = 5/group). 
The result exhibited a high accumulation in the reticuloendothelial system (RES) including the 
liver and spleen, Figure 4.12. Over 16.83% ID ALL*-GNS, the second highest accumulation, 
was retained in the tumor at 2 hour post-injection, which was similar with previous report [384]. 
The concentration of gold 24 hours after injection remained high in RES, while the uptake in the 
other organs decreased significantly. 
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4.3.3 Cytotoxicity of GPC3 targeting GNS in vitro 
In vitro viability of GNSs treated Hep3B cells was calculated as a percentage relative to that of 
cells treated with the same volume of PBS (whose viability was arbitrarily defined as 100%). 
GNS solutions at concentrations of 1×1010, 5×1010, 1×1011, and 5×1011, 1×1012 GNSs/mL were 
applied to cells for 24 h. All treated cells resulted in viabilities above 91% regardless of surface 
chemistry. Error bars represented standard deviations of five separate measurements, Figure 4.13. 
 
Figure 4.13 Cytotoxicity of gold GNSs. More than 91% of cultured Hep3B cells survived after incubating with bare or surface 
modified GNS for 24 hours. 
4.3.4 Biosafety of GPC3 targeting GNS in vivo 
The body weight of mice was measured every other day for 16 days following systemic 
administration of PBS, GNS-PEG and ALL*-GNS, respectively. It’s noteworthy that despite the 
high accumulation in RES, the body weight of mice did not show significant change over 2 
weeks as shown in Figure 4.14, indicating the excellent biocompatibility of GNS in vivo. 
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Figure 4.14 Change of body weight in mice after gold nanoshell injection. Mouse body weight was monitored over 16 days for 
the PBS, GNS-PEG, and ALL*-GNS treated groups (n = 5/group). 
4.4 Discussions 
While a wide variety of nanoparticles such as carbon nanotubes and gold nanostructures 
provided a platform for signal enhancement [329, 385], each possesses certain unique 
characteristics suitable for different applications. Examples of nanoparticles that can be used to 
label peptides for increased signal include iron oxide [83], CuS [386], gold nanorods [75], gold 
nanospheres [79, 387], carbon nanotubes [84, 238] and polymer nanoparticles [388-391]. Carbon 
nanotubes are considered more biocompatible [392], absorb over a broad spectrum [318], and 
possess superior photoacoustic signal strengths compared to metallic NPs[393]. Polymer NPs 
can be more photostable than gold nanorods and photoacoustically brighter than carbon 
nanotubes with pulsed laser irradiation [394, 395]. Despite not giving the utmost photoacoustic 
contrast among all nanoparticles, metallic nanoparticles have easily tunable and very strong 
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absorption that can also be used for photothermal therapy after tumor delivery [85, 396-398], 
which is aligned with the proposed future work in multispectral labeling in Section 5.1.2 and 
photothermal therapy in Section 5.1.6. Furthermore, spherical solid gold nanoparticles with 100-
150 nm diameters have plasmon resonance peaks in the visible region (572-614nm), and thus 
will not be resonant in the NIR range for photoacoustic imaging [399]. Therefore, gold nanoshell 
with NIR resonance peak was used in this study. 
Different nanoparticle sizes can have implications in terms of probe delivery and biodistribution. 
Nanoparticles with diameters smaller than 6 nm are quickly eliminated from the body because 
they can be excreted by the kidneys [220] and thus not suitable for our targeted probe delivery 
application. On the other hand, nanoparticles with diameters larger than 200 nm tend to 
accumulate in the spleen and liver [400], where they are endocytosed by the MPS cells [401]. 
Previous study on the effect of size (15—200nm) on gold nanoparticle biodistribution after 
intravenous administration revealed gold NPs of all sizes were mainly accumulated in organs 
like liver, lung and spleen [402]. They also found that 15 and 50 nm GNPs were able to pass 
blood-brain barrier (BBB) [402, 403]. Such uncontrolled passage into the brain may not be 
desirable in translation of small nanoparticle into clinical applications. The size dependent 
biodistribution of nanoparticles narrowed down our probe size choice in the 50—200 nm range. 
In order to reduce the non-specific accumulation of GPC3-targeting nanoshells in healthy tissues, 
especially liver and spleen, greater than 100 nm size of nanoparticle were used. When injected 
into the blood stream, the delivery of nanoparticles to tumor site via passive accumulation 
through the leaky tumor vasculature is known as enhanced permeability and retention (EPR) 
effect [79, 213]. The EPR effect varies between tumor types [404], but in general favors 
accumulation of sub-100nm structures [405]. It was demonstrated that tumor accumulation can 
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be mediated by high nanoparticle avidity and are weakly dependent on their plasma clearance 
rate [405]. The photoacoustic signal in tumors after targeting probe injection represents the 
combined effect of targetability and EPR effect, while that after scrambled control probe 
injection resulted solely from EPR effect which was mostly confined within the blood vessels.  
Finally, two more competing forces dictated the nanoprobe choice for targeted in vivo 
photoacoustic imaging study presented above. On one hand, the absorption contribution to light 
extinction property of gold nanoshells decreases as the overall diameter increases [215, 338, 339]. 
On the other hand, passage into the brain extracellular space can be restricted if the size of a 
nanocarrier exceeds 100 nm [406]. While the upper limit of pore size in the BBB that enables 
passive flow of molecules across it is usually <1 nm, particles with tens of nanometers in size 
[407] can also cross the BBB by carrier-mediated transport [408]. Thus in this study we chose 
GNSs of medium size (136.3±7.7nm) to prevent brain accumulation and maximize light 
absorption for strong PA signal.  
Under regulated biomarkers is one major hallmark of malignant tumor [409]. Overexpression of 
GPC3 expedites tumor invasion and metastasis [410]. Therefore, in the new era of precision 
medicine, imaging tumor associated biomarkers is critical for assessing the tumor behavior, 
predicting the therapeutic response and maximizing the treatment benefit. Benefited from the 
sensitivity of PAI and PA-enhancing effect of ALL*-GNS, we extended the imaging depth to 
centimeters under skin in vivo with fast imaging speed and high spatial resolution. It is 
interesting to note that we used a laser fluence of ~2.5 mJ/cm2, which is much lower than the 
ANSI safety limit for skin exposure (~20 mJ/cm2) [411]. Future research would extend this work 
to targeted treatment of HCC such as photothermal therapy to achieve localized ablation of 
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tumor through heat absorption of GNS. With further development, this theranostic platform can 
be promising in clinical translation. 
4.5 Summary 
Compared to in vivo photoacoustic imaging with Cy5.5-labled peptide, PAI with GPC3 targeting 
gold nanoshells visualized HCC tumors at greater depth (2.1cm vs 1.8cm), with improved 
contrast (T/B = 4.45 vs 2.25) at peak tumor uptake and faster pharmacokinetics (peak time = 
2hrs vs 3hrs, clearance time = 12 hrs vs 24 hrs). Injection of control peptide coated GNSs 
validated specificity of targeted nanoprobe accumulation independent of EPR effect. Cell 
viability and in vivo toxicity studies ensured biosafety and biocompatibility of ALL*-GNS for 
systemic delivery. In vivo imaging via photoacoustic tomography with molecular probe 
conjugated GNS offers a safe, effective and rapid imaging technique for noninvasive in vivo 
monitoring and semi-quantitative analysis of HCC tumor growth and GPC3 expression with 
great clinical translation potential. 
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Chapter 5 Future work and conclusions 
5.1 Future studies 
We propose further studies encompassing four themes: biomarker (differential expression in 
subpopulations and biomarker panel for diagnosis), imaging (orthotopic/PDX tumor model), 
surgical planning (3D-printed tumor microenvironment) and therapy (GNS mediated PTT and 
targeted drug delivery). Preliminary results toward these future directions are discussed below. 
5.1.1 Differential GPC3 expression in patient subpopulations 
A closer examination of the patient gene expression profile data presented in Figure 3.1 revealed 
differential GPC3 expression levels among patient subpopulations categorized by etiologies, a 
phenomenon found by other researchers as well [412]. While HCC tumors (T) showed higher 
expression with both hepatitis B virus (HBV) and hepatitis C virus (HCV) infection had a 
significantly higher (2.6 and 7.7 fold-changes, P=1.6×10-5 and P=2.1×10-16 respectively) GPC3 
expression compared to normal (N) liver tissue within the same infection, overexpression in 
HCV cases was much more elevated (3.2 fold-change, P=4.7×10-5) than those in HBV cases, 
Figure 5.1. The question remains whether the same pattern can be found in protein expression 
levels of GPC3 in different HCC subpopulations. The sample size in our human tissue 
experiment was not big enough to draw conclusions. Immunochemical studies involving more 
human HCC patient biopsy samples from each disease background would be one way to test this 
hypothesis. 
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Figure 5.1 Differential GPC3 overexpression in HCC patient subpopulations. While HCC tumors (T) showed higher expression 
with both hepatitis B virus (HBV) and hepatitis C virus (HCV) infection had a significantly higher (2.6 and 7.7 fold-changes, 
P=1.6×10-5 and P=2.1×10-16 respectively) GPC3 expression compared to normal (N) liver tissue within the same infection, 
overexpression in HCV cases was much more elevated (3.2 fold-changes, P=4.7×10-5) than those in HBV cases. 
5.1.2 Multispectral tumor imaging with nanoparticles 
Common to most of cancers, heterogeneity in genetic expression across different patients is an 
essential characteristic of HCC [412]. HCC can present a combination of various biomarkers 
(Section 3.1.1), and not a single biomarker is expected to express in all HCC patient population. 
To detect HCC lesion with greater sensitivity, a panel of peptides against different targets can be 
utilized. GPC3 and EGFR are overexpressed in 40-70% and 80% in HCC respectively. We have 
so far developed peptides that target GPC3 and EGFR. Administer the two peptides 
simultaneously could expand our knowledge on HCC development by answering some key 
questions such as the co-expressing rate of GPC3 and EGFR in various stages of HCC. 
Meanwhile, some practical concerns over the interaction, or even competition, between peptide 
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probes in the combination formula and how it should be administered (simultaneously vs 
sequentially) must be taken into consideration in the experiment design. 
 
Figure 5.2 GPC3 and EGFR peptides binds to human HCC tissue sections. Immunofluorescent staining was performed on human 
HCC liver tissue with (A) GPC3-targeting peptide ALL*-Cy5.5 (red, intense staining), (B) scrambled control peptide QLE*-
Cy5.5 (red, negative staining), (C) AF488 labeled anti-GPC3 antibody (green). (D) Immunohistochemical staining of HCC tissue 
with anti-GPC3 antibody and (E) corresponding histological section with H&E staining. Similarly, immunofluorescent staining 
was performed on human HCC liver tissue with (F) EGFR-targeting peptide QRH*-Cy5.5 (red, intense staining), (G) scrambled 
control peptide PEH*-Cy5.5 (red, negative staining), (H) AF488 labeled anti-EGFR antibody (green). (I) Immunohistochemical 
staining of HCC tissue with anti-EGFR antibody and (J) corresponding histological section with H&E staining. 
Preliminary results of positive staining by individual peptide probes on human biopsies showed 
potential for a more sensitive diagnostic tool with two peptides combined. On confocal 
microscopy, we found intense staining of GPC3 targeting peptide ALL*-Cy5.5 (red) to sections 
of human hepatocellular carcinoma, Figure 5.2(A), compared to control peptide, Figure 5.2(B). 
Increased fluorescence intensity was observed for staining of anti-GPC3-AF488 antibody (green) 
to human hepatocellular carcinoma, Figure 5.2(C). On immunohistochemistry with a known 
antibody, we confirmed overexpression of GPC3 in human HCC, Figure 5.2(D). Corresponding 
H&E histology of HCC is shown in Figure 5.2(E). Similarly, EGFR targetability by QRH-Cy5.5 
peptide and EGFR overexpression in human HCC tissue sections are shown in Figure 5.2(F-J). 
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Labeling of probes is one of the key issues to be addressed for multispectral detection [413]. 
Spectrally distinct label for each targeting probe in the mix is preferred since share label 
wouldn’t be able to keep track of the identity of biomarker being detected. Coating of metallic 
shells on silica allows one to tune the absorption band from visible to infrared region [325]. The 
position of the SPR band is sensitive towards relative thickness of core-to-shell ratio [414]. Thus 
by changing the shell thickness, one can tune the SPR band position in the desired wavelength 
range, Figure 5.3. Metallic nanoshells having plasmon resonance in the infrared region are well 
suited for biological applications, as this range of the electromagnetic spectrum is transparent for 
biological tissues [415]. Therefore it is possible to label EGFR and GPC3 targeting peptides with 
gold nanoshells of different SPR and perform multispectral imaging to illuminate the roles each 
biomarker plays in HCC development and how they interact with each other. 
 
Figure 5.3 Tuning SPR band by core to shell ratio of GNS. As core-to-shell ratio of gold nanoshells increases, its peak absorption 
wavelength (i.e. SPR band) shifts to the right of spectrum (i.e. longer wavelength). 
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5.1.3 Orthotopic and patient derived xenograft 
The biodistribution results in Section 3.6.2 raised the concern that fluorescent signal from liver 
could mask tumor signal should the xenograft were implanted on the liver, which could hinder 
the clinical translation of image guided surgery. Orthotopic tumor model of HCC can address 
this issue while patient derived xenograft (PDX) can recapitulate the genetic heterogeneity [416-
418] discussed in Section 5.1.2. In a preliminary study, we examined the pharmacokinetics of 
Cy5.5 labeled ALL* displaying and wildtype (WT-phage) phages in mice (n=5 in each group) 
bearing orthotopic HCC tumor (from Hep3B cells). We observed accumulation of ALL*- phages 
to the site of liver xenograft with a distinctive peak at 1.5hrs after tail vein injection of 2*1011 
pfu ALL*- phages, Figure 5.4(A). Minimal signal remained in liver after 24 hours and some 
showed up in the bladder, indicating the path of probe clearance through urinary tract. In contrast, 
mice (n=5) injected with WT- phages also saw accumulation in the liver presumably due to the 
high vascularity and the probe being metabolized in the liver, Figure 5.4(B). Signal from the NIR 
dye peaked at 30min and gradually tapered off until 24 hours. All images were quantified in term 
of normalized photon flux (mean±SD) and plotted in Figure 5.4(C). This preliminary result 
added confidence in the ability of peptide to generate visible contrast at tumor from surrounding 
liver tissue even after signal was attenuated through the muscles and skin. However, additional 
studies are needed before solid conclusions can be drawn, such as imaging using synthesized 
peptides rather than phages, inoculating orthotopic tumors with patient derived xenografts rather 
than standard HCC cell lines, and examination of tumor margin at peak uptake time by dissecting 
the liver. 
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Figure 5.4 In vivo GPC3 targeting in orthotopic HCC mouse model. (A) nude mice with orthotopically embedded HCC tumor 
(arrow) in the liver was underwent whole-body fluorescent imaging after tail vein injection of Cy5.5 labeled ALL*-phages over 
the time course of four hours. Peak fluorescent signal was observed at 1.5 hours post injection. (B) Cy5.5 labeled wild type 
phages showed some fluorsent intensity increase at the tumor at 0.5 hr post injection. (C) fluorescent signal from GPC3-targeting 
peptide dysplaying phage peaked at 1.5 hours and was significantly higher than that of wild type phages (3.1×1010 ±9.8×109vs. 
3.5×109±2.3×109, P=3.6 ×10-3). 
5.1.4 3D printing for surgical planning 
While originally conceived of as a way to help surgeons with complicated or extremely delicate 
surgical procedures, doctors are discovering some unexpected benefits from using 3D printed 
replicas of patients’ organs for surgical preplanning for more common surgeries [419-421]. So 
much of the surgical techniques that are used today involve surgical preplanning using MRI or 
CT data [422], which provides an image of exactly what the surgeon will be cutting into, 
especially when the doctor is using laparoscopic or robotic surgical tools [423, 424]. 3D data 
from photoacoustic tomography imaging in this thesis were presented as a 2D images, which 
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may not always give surgeons the clearest picture of tumor location. Turning that 3D data into a 
3D printable model allows doctors to get a much better idea of the tumor’s blood supply and 
microenvironment, and make better treatment recommendations and surgical plans.  
The photoacoustic image of HCC tumor in Figure 4.10 can be segmented and rendered into a 3D 
spatial structure for both the tumor (pink) and the blood vessels (gold) around it, as shown in 
Figure 5.5. A real life size, or even scaled up, 3D polymer model could be printed with a 3D 
printer. This would not only help doctors offer patients more accurate treatment options, but also 
allow the actual surgical procedure to go smoother for the surgeons. Knowing exactly there the 
vessels lied around the tumor could also minimize bleeding and reduce surgery time.  
 
 
Figure 5.5 3D PAI model of HCC lesion with surrounding blood vessels. 3D reconstructed photoacoustic image can be 3D 
printed as physical model for surgery planning. Tumor (pink) was segmented from surrounding vasculature (gold). 
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5.1.5 Targeted chemotherapy  
Targeted drug delivery can improve the efficacy of chemotherapy by increasing drug 
concentration at tumor site while reducing cytotoxicity at healthy tissue [425, 426]. GPC3 has 
proven to be an attractive chemotherapy target for HCC [53, 245]. Cell surface GPC3 is believed 
to promote tumor growth and development [244, 427]. Recent studies have elucidated the role of 
GPC3 as co-receptor or storage pocket for several growth factors including Wnts, FGFs and 
bone morphogenetic proteins [247, 262, 263, 265, 267]. In addition, silencing GPC3 expression 
by siRNA or shRNA in HCC cell lines HepG2, Hep3B, Huh-7 and Huh-4 can inhibit cell 
proliferation [272, 428]. Interruption of the interactions between GPC3 and various signaling 
pathways may induce tumor cell death and ablation of tumor growth [128]. Four GPC3 
antibodies are being developed for liver cancer therapy [261, 272, 429-431]. Humanized mouse 
antibody GC33 has undergone phase I clinical trials for advanced or metastatic HCC either alone 
or in combination with FDA-approved chemo drug sorafenib [429]. The specific binding affinity 
of ALL* to GPC3 can be exploited by incorporating chemotherapeutic drugs in nanoplatforms 
using ALL* for HCC-targeted drug delivery and therapy. 
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5.1.6 Photothermal therapy 
 
 
Figure 5.6 GPC3 targeting GNS as theranostic agent. Targeted gold nanoshell delivers photothermal therapy under photoacoustic 
imaging guidance in HCC. 
The GPC3 targeting photoacoustic probe is a promising nano theranostic platform for target 
specific tumor imaging and localized photothermal therapy [432-434], Figure 5.6. The extent of 
thermal damage to tissue depends on tissue sensitivity, temperature and exposure time [435-437]. 
In vitro studies showed that the rate of cell death is exponential with respect to temperature over 
a limited temperature range (40–55 °C) [438, 439]. PTT of 3W/cm2 coherent diode laser (808nm) 
for 3 minutes at a single tumor site can slow the growth of distant pre-established melanoma 
tumors in three weeks [440]. Nanoshell-treated tumors resulted in an average temperature 
increase of 37.4 ± 6.6°C on NIR (820nm) exposure for 4–6 min [441]. This therapy raised 
temperatures well above the damage threshold necessary to induce irreversible tissue damage 
[442] and did so by using laser dosages that were 10- to 25-fold less than those used in earlier 
studies with ICG [443].  
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The targeted delivery of photothermal nanotherapeutics can achieve noninvasive, localized 
imaging guided photothermal ablation of HCC in vivo [444, 445]. Metallic NPs can be used in 
tandem with infrared heating for therapy; nanoshells and nanorods are the most common 
examples [330, 383, 399, 446, 447]. By using two benign moieties (NIR light and nanoshells), 
The GPC3 specific gold nanoshell enabled photothermal therapy (PTT) as a promising ablation 
strategy that utilizes optically tuned gold nanoshells to generate heat upon exposure to near-
infrared radiation [383]. Moreover, the combination of PTT with immunotherapy can improve 
the therapeutic efficacy on both primary tumor and metastatic cancer cells in the distant sites in a 
complementary manner [447-449]. Bear et al found gold nanoshell based PTT could promote the 
expression of proinflammatory cytokines and chemokines, and induce the maturation of dendritic 
cells (DC) within tumor-draining lymph nodes, leading to the priming of antitumor CD8+ 
effector T cell responses [447]. However, nanoparticles are foreign bodies that can cause 
inflammation in liver [450, 451] and increase circulation time [452]. Among nanomaterial-based 
agents already approved by the FDA [453], all but one of these agents are therapeutics [454]. 
Thus PTT with targeted GNS can be a great way to push forward regulatory approval of 
theranostics nanoparticle agents in the clinic. 
5.2 Conclusions 
Molecular cancer imaging strategy was proposed to address an important clinical problem, the 
accurate detection of hepatocellular carcinoma (HCC). Targeted peptide probes against cell 
surface molecules of biological significance, EGFR and Glypican-3, have been successfully 
developed and characterized. Longitudinal studies in the mouse model of HCC have been 
demonstrated using various in vivo imaging systems. In parallel, the application of these probes 
after fluorescent labeling for photoacoustic imaging was also investigated. While photoacoustic 
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imaging produces anatomical and physiological information of cancer, this work improved the 
technique by using molecularly targeted image contrast for cancer by using affinity peptides 
targeted to cancer cells. Findings in regards to the specificity of each of the probes, binding 
efficiency and bioavailability was investigated in cultured cells, in ex vivo tissues (human and 
mouse) as well as in mouse models. These targeting probes showed great promise for clinical 
translation with high specificity, sensitivity and fast pharmacokinetics. The findings provide 
compelling evidence that the developed imaging agents have the desired specificity and 
sensitivity as well as biocompatibility for future clinical translation. Further development and 
research would extend this work to better diagnosis, imaging and targeted treatment of HCC. 
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